Article

Immunity

CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity

Graphical abstract



Highlights

- Analyses of SARS-CoV-2-specific CD8+ T cells *ex vivo* using peptide-HLA tetramers
- Tetramer-specific CD8+ T cells in unexposed individuals display a naive phenotype
- B7/N105+CD8+ T cells are seen in high numbers during COVID-19 and persist long term
- High naive frequency and TCR plasticity underpin dominant B7/N105+CD8+ T cells

Authors

Thi H.O. Nguyen, Louise C. Rowntree, Jan Petersen, ..., Jamie Rossjohn, Joseph Torresi, Katherine Kedzierska

Correspondence

kkedz@unimelb.edu.au

In brief

Examining unmanipulated SARS-CoV-2-specific T cells is important for understanding primary and recall responses during COVID-19. Nguyen et al. analyze *ex vivo* CD8+ T cells specific for SARS-CoV-2 epitopes and find that immunodominant B7/N105-specific CD8+ T cells are present at high frequencies in blood samples from unexposed, acute COVID-19, and convalescence individuals, which is underpinned by diverse TCR repertoires.

Nguyen et al., 2021, Immunity *54*, 1066–1082
May 11, 2021
https://doi.org/10.1016/j.immuni.2021.04.009

CellPress

CellPress

Immunity

Article

CD8+ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity

Thi H.O. Nguyen,[1,29] Louise C. Rowntree,[1,29] Jan Petersen,[2,3,29] Brendon Y. Chua,[1,4] Luca Hensen,[1] Lukasz Kedzierski,[1,5] Carolien E. van de Sandt,[1,6] Priyanka Chaurasia,[2] Hyon-Xhi Tan,[1] Jennifer R. Habel,[1] Wuji Zhang,[1] Lilith F. Allen,[1] Linda Earnest,[1] Kai Yan Mak,[1] Jennifer A. Juno,[1] Kathleen Wragg,[1] Francesca L. Mordant,[1] Fatima Amanat,[7,8] Florian Krammer,[7] Nicole A. Mifsud,[2] Denise L. Doolan,[9] Katie L. Flanagan,[10,11,12,13] Sabrina Sonda,[10] Jasveen Kaur,[10,13] Linda M. Wakim,[1] Glen P. Westall,[14] Fiona James,[15] Effie Mouhtouris,[15] Claire L. Gordon,[1,15] Natasha E. Holmes,[15,16,17]

(Author list continued on next page)

[1]Department of Microbiology and Immunology, University of Melbourne, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia
[2]Infection and Immunity Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC 3800, Australia
[3]Australian Research Council Centre of Excellence for Advanced Molecular Imaging, Monash University, Clayton, VIC 3800, Australia
[4]Global Station for Zoonosis Control, Global Institution for Collaborative Research and Education (GI-CoRE), Hokkaido University, Sapporo 060-0808, Japan
[5]Faculty of Veterinary and Agricultural Sciences, University of Melbourne, Melbourne, VIC 3000, Australia
[6]Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam 1066CX, the Netherlands
[7]Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
[8]Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
[9]Centre for Molecular Therapeutics, Australian Institute of Tropical Health & Medicine, James Cook University, Cairns, QLD 4870, Australia
[10]School of Health Sciences and School of Medicine, University of Tasmania, Launceston, TAS 7248, Australia
[11]Department of Immunology and Pathology, Monash University, Commercial Road, Melbourne, VIC 3004, Australia
[12]School of Health and Biomedical Science, RMIT University, Melbourne, VIC 3000, Australia
[13]Tasmanian Vaccine Trial Centre, Clifford Craig Foundation, Launceston General Hospital, Launceston, TAS 7250, Australia
[14]Lung Transplant Unit, Alfred Hospital, Melbourne, VIC 3004, Australia
[15]Department of Infectious Diseases, Austin Hospital, Heidelberg, VIC 3084, Australia

(Affiliations continued on next page)

SUMMARY

To better understand primary and recall T cell responses during coronavirus disease 2019 (COVID-19), it is important to examine unmanipulated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cells. By using peptide-human leukocyte antigen (HLA) tetramers for direct *ex vivo* analysis, we characterized CD8+ T cells specific for SARS-CoV-2 epitopes in COVID-19 patients and unexposed individuals. Unlike CD8+ T cells directed toward subdominant epitopes (B7/N_{257}, A2/S_{269}, and A24/$S_{1,208}$) CD8+ T cells specific for the immunodominant B7/N_{105} epitope were detected at high frequencies in pre-pandemic samples and at increased frequencies during acute COVID-19 and convalescence. SARS-CoV-2-specific CD8+ T cells in pre-pandemic samples from children, adults, and elderly individuals predominantly displayed a naive phenotype, indicating a lack of previous cross-reactive exposures. T cell receptor (TCR) analyses revealed diverse TCR$\alpha\beta$ repertoires and promiscuous $\alpha\beta$-TCR pairing within B7/N_{105}+CD8+ T cells. Our study demonstrates high naive precursor frequency and TCR$\alpha\beta$ diversity within immunodominant B7/N_{105}-specific CD8+ T cells and provides insight into SARS-CoV-2-specific T cell origins and subsequent responses.

INTRODUCTION

As global research efforts are moving at record speed to develop and evaluate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, concurrent efforts are needed to provide an understanding of the optimal immune responses in coronavirus disease 2019 (COVID-19), thus enabling the rational design of long-lasting and broadly protective vaccines and immunotherapies. Virus-specific CD8+ T cells can greatly ameliorate recovery from respiratory diseases such as

Olivia C. Smibert,[15,18,19] Jason A. Trubiano,[18,19,20,21] Allen C. Cheng,[22,23] Peter Harcourt,[24] Patrick Clifton,[24] Jeremy Chase Crawford,[25] Paul G. Thomas,[25] Adam K. Wheatley,[1,26] Stephen J. Kent,[1,26,27] Jamie Rossjohn,[2,3,28] Joseph Torresi,[1] and Katherine Kedzierska[1,4,30,*]

[16]Department of Medicine and Radiology, The University of Melbourne, Parkville, VIC 3000, Australia
[17]Data Analytics Research and Evaluation (DARE) Centre, Austin Health and The University of Melbourne, Heidelberg, VIC 3084, Australia
[18]Department of Infectious Diseases, Peter McCallum Cancer Centre, Melbourne, VIC 3000, Australia
[19]The National Centre for Infections in Cancer, Peter McCallum Cancer Centre, Melbourne, VIC 3000, Australia
[20]Centre for Antibiotic Allergy and Research, Department of Infectious Diseases Austin Health, Heidelberg, VIC 3084, Australia
[21]Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, VIC 3084, Australia
[22]Infection Prevention and Healthcare Epidemiology Unit, Alfred Health, Melbourne, VIC 3004, Australia
[23]School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC 3004, Australia
[24]AFL House, Melbourne, VIC 3001, Australia
[25]Department of Immunology, St Jude Children's Research Hospital, Memphis, TN 38105, USA
[26]ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of Melbourne, Melbourne, VIC 3000, Australia
[27]Melbourne Sexual Health Centre, Infectious Diseases Department, Alfred Health, Central Clinical School, Monash University, Melbourne, VIC 3004, Australia
[28]Institute of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff CF14 4XN, United Kingdom
[29]These authors contributed equally
[30]Lead contact
*Correspondence: kkedz@unimelb.edu.au
https://doi.org/10.1016/j.immuni.2021.04.009

avian influenza, SARS, and Middle East respiratory syndrome (MERS) (Channappanavar et al., 2014; Wang et al., 2015; Wang et al., 2018; Zhao et al., 2017) and persist long-term as cross-reactive memory pools (Koutsakos et al., 2019). Therefore, understanding human epitope-specific CD8$^+$ T cell responses to SARS-CoV-2 directly *ex vivo* is needed to better define the role of CD8$^+$ T cells in primary SARS-CoV-2 infection, long-term memory persistence, and their subsequent recall after re-infection and/or vaccination.

SARS-CoV-2-specific CD8$^+$ T cells can be elicited during primary COVID-19 and survive into short-term convalescence (Dan et al., 2021). Activated CD8$^+$ T cells, displaying a broad range of cytotoxic molecules, appear in patients' blood prior to recovery (Koutsakos et al., 2021; Thevarajan et al., 2020), suggesting involvement of CD8$^+$ T cells in the resolution of COVID-19. Activated T cells directed toward spike (S), membrane (M), nucleocapsid (N) and other open reading frames can be detected in ~70% of acute and convalescent COVID-19 patients by utilizing human leukocyte antigen (HLA) class I and II predicted peptide "megapools" to stimulate peripheral blood mononuclear cells (PBMCs) (Grifoni et al., 2020; Weiskopf et al., 2020). Stimulation of PBMCs from COVID-19 patients with SARS-CoV-2 overlapping peptides also leads to interferon (IFN)-γ production and clonal expansion of CD8$^+$ T cells *in vitro*. Thus, both *ex vivo* and *in vitro* studies indicate that CD8$^+$ T cells get activated during primary SARS-CoV-2 infection.

SARS-CoV-2 CD8$^+$ T cell epitopes (peptides + major histocompatibility complex [MHC]-I) are identified for dominant HLA class I alleles, including HLA-A*01:01, A*02:01, A*03:01, A*11:01, HLA-B*07:02, B*27:05, B*40:01, and B*44:03, by using both peptide stimulations and peptide-MHC class I tetramers (Ferretti et al., 2020; Habel et al., 2020; Peng et al., 2020; Schulien et al., 2021). Identification of SARS-CoV-2 CD8$^+$ T cell epitopes allows accurate determination of the magnitude and phenotype of SARS-CoV-2-specific CD8$^+$ T cells directly *ex vivo* in COVID-19 patients and in pre-pandemic PBMCs. It also allows us to precisely define the persistence of long-term memory CD8$^+$ T cells and their recall after SARS-CoV-2 re-infection and/or vaccination. *Ex vivo* frequencies of SARS-CoV-2-specific CD8$^+$ T cells appear to be present mainly in the range of $\sim1 \times 10^{-5}$ to 5×10^{-5} in the CD8$^+$ T cell population, which is ~2- to 10-fold lower than the frequency of long-term memory CD8$^+$ T cells specific for influenza or Epstein-Barr virus (EBV). HLA-A*02:01-restricted SARS-CoV-2 epitopes appear to exhibit the lowest frequency of $\sim1 \times 10^{-5}$ in the CD8$^+$ T cell population (Habel et al., 2020; Peng et al., 2020). Direct *ex vivo* phenotypic analysis of A2/$S_{269}$$^+$CD8$^+$ T cells from COVID-19 convalescent individuals revealed that A2/$S_{269}$$^+$CD8$^+$ T cells were suboptimally stimulated and composed of naive, stem cell memory, and central memory T cells rather than effector memory populations. In contrast, the HLA-B*07:02-restricted $N_{105\text{-}113}$ epitope (B7/N_{105}) appears to be the most dominant SARS-CoV-2 CD8$^+$ T cell specificity known to date (Ferretti et al., 2020; Peng et al., 2020; Schulien et al., 2021), applicable to 1 in 12 people globally (Gonzalez-Galarza et al., 2020). The question remains, however, whether these immunodominant B7/$N_{105}$$^+$CD8$^+$ T cell responses arise from pre-existing memory pools established after infection with a cross-reactive seasonal human coronavirus or other pathogens, or whether they represent a high frequency of naive pools found across HLA-B*07:02-expressing individuals.

To provide an in-depth understanding of CD8$^+$ T cell responses directed at the immunodominant B7/N_{105} epitope, we performed direct *ex vivo* analyses in PBMCs from COVID-19 patients as well as in pre-pandemic PBMCs, tonsils, lungs, and spleens. With *ex vivo* tetramer enrichment, single-cell reverse transcriptase (RT)-PCR, and *in vitro* IFN-γ/tumor necrosis factor (TNF) intracellular cytokine secretion (ICS) assay, we determined the magnitude, naive/effector/memory phenotype, and molecular T cell receptor (TCR)$\alpha\beta$ signatures. Overall, we assessed CD8$^+$ T cells directed at 4 SARS-CoV-2 epitopes: B7/N_{105}, B7/N_{257}, A2/S_{269}, and A24/S_{1208}. In contrast to the 3 subdominant SARS-CoV-2-specific CD8$^+$



(legend on next page)

T cell populations, B7/N_{105}-specific CD8$^+$ T cell pools were numerically immunodominant by 4.89- to 38.03-fold in both COVID-19 patients and pre-pandemic donors. Tetramer-specific CD8$^+$ T cell populations directed at all 4 SARS-CoV-2 epitopes were predominantly of a naive phenotype in 22 of the 27 pre-pandemic donors. Together with the TCR data, the findings support our conclusion that high precursor frequency and promiscuity in $\alpha\beta$ TCR pairing could underpin CD8$^+$ T cell responses to an immunodominant SARS-CoV-2 nucleocapsid epitope.

RESULTS

COVID-19 patient cohort and pre-pandemic controls

We recruited a total of 21 COVID-19 subjects, including 8 acute hospitalized patients and 13 convalescent COVID-19 patients (Figure 1A; Table S1). Of the 8 patients hospitalized, 1 ICU and 3 ward patients required oxygen support. Ten of the convalescents were community SARS-CoV-2 infections. All COVID-19 patients seroconverted for SARS-CoV-2 antibodies. The median age of COVID-19 patients was 54 years, and 33% of patients were females. As controls, we analyzed pre-pandemic PBMC and tonsil samples from 31 subjects across 3 age groups: 4 children (median age 6 years, range 3–15), 20 adults (median age 46 years, range 24–63) and 7 elderly (median age 72 years, range 65–76), 37.6% were females. Additionally, we tested pre-existing B7/CD8$^+$ T cell populations in lung and spleen tissues from 9 HLA-B7 individuals (median age 46 years, range 22–63).

Within this study, a traveler cohort included 3 male SARS-CoV-2 cases (a 19-year-old CA3 index case with moderate COVID-19, 1 21-year-old CA2 individual with mild symptoms, and 1 24-year-old CA1 individual who remained asymptomatic; Table S1). Four asymptomatic suspected cases (SU1, SU2, SU3, SU4; all 20 years old) were also investigated. All were returned travelers. Receptor binding domain (RBD) and spike immunoglobulin (Ig)G antibody levels were significantly ($p < 0.05$) higher in cases ($\log_{10}$ median titer 3.195 RBD IgG; 3.237 spike IgG) than in suspected cases ($\log_{10}$ median titer 1.762 RBD IgG; 1.994 spike IgG) and in healthy unexposed individuals ($\log_{10}$ median titer 2.024 RBD IgG; 2.239 spike IgG) (Figure S1A). IgM titers in COVID-19 cases were significantly elevated in comparison with those found in healthy unexposed individuals (Figure S1A). RBD- and spike-reactive B cell responses were concordant with the antibody titers and showed significantly increased frequencies of RBD- and spike-specific B cells in COVID-19 cases when compared to the suspected cases (Figures S1B–S1D). Minimal immune cell activation across a broad range of cell populations (CD56$^+$ NK cells, CD3$^+$ $\gamma\delta$ T cells, CD8$^+$ T cells, CD4$^+$ T cells, antibody-secreting cells [ASCs], T follicular helper cells [Tfhs], and monocytes), low granzyme/perforin levels within CD8$^+$ and CD4$^+$ T cells, and normal inflammatory milieu (Figure S2) verified lack of acute COVID-19 in the traveler cohort.

CD4$^+$ and CD8$^+$ T cell responses react to SARS-CoV-2 overlapping peptide pools

Probing SARS-CoV-2-specific CD4$^+$ and CD8$^+$ T cells in the traveler cohort was performed by using overlapping SARS-CoV-2 peptide pools spanning the entire N and M proteins and the immunogenic regions of S protein, followed by an ICS assay (Figure 1B). PBMCs were stimulated with 1 peptide pool, expanded for 10 days before the analysis of SARS-CoV-2-reactive T cells by ICS for intracellular IFN-γ, TNF, MIP-1β, and CD107a (Figure 1B; Figure S3A). In agreement with the antibody and B cell data, SARS-CoV-2-reactive CD4$^+$ and CD8$^+$ T cells were detected in COVID-19 cases but not in the suspected cases, with CD4$^+$ T cells generally dominating over CD8$^+$ T cell populations, as previously reported (Habel et al., 2020). No differences were observed between the responses against S, N, and M proteins for both CD4$^+$ and CD8$^+$ T cells (Figure 1B, right panel). The exception was CA2 with highly prominent CD8$^+$ T cell responses directed toward the N peptide pool (IFN-γ production up to ~25% of CD8$^+$ T cells), markedly above IFN-γ-producing CD4$^+$ T cells (range 0.24%–1.15%) (Figure 1C). Because CA2 was HLA-B*07:02$^+$ and HLA-A*02:01$^+$ (Table S1), we further dissected the CD8$^+$ T cell response to 5 previously reported immunogenic peptides derived from N and restricted by both HLA-B*07:02 and HLA-A*02:01 (B7/N_{66}, B7/N_{105}, B7/N_{257}, A2/N_{219}, and A2/N_{222}) (Ferretti et al., 2020; Schulien et al., 2021). In CA2, immunodominant CD8$^+$ T cell responses were directed toward B7/N_{105}, whereas subdominant CD8$^+$ T cell responses were against B7/N_{257}, as shown by both IFN-γ production toward those peptides and B7/N_{105}, B7/N_{257}, and B7/N_{66} tetramer staining (Figure 1D; Figure S3B).

Immunodominant B7/$N_{105}$$^+$CD8$^+$ T cells possess a high precursor frequency

To determine the magnitude of SARS-CoV-2-specific CD8$^+$ T cell populations in 19 COVID-19 patients and 23 pre-pandemic unexposed individuals expressing HLA-B*07:02, HLA-A*02:01, and/or HLA-A*24:02, we used tetramer-associated magnetic enrichment (TAME) directly *ex vivo* (Nguyen et al., 2017b; Valkenburg et al., 2016) for the immunodominant B7/N_{105} and

Figure 1. CD4$^+$ and CD8$^+$ T cell responses to SARS-CoV-2 overlapping peptide pools and individual SARS-CoV-2 HLA-B*07:02-restricted peptides

(A) Overview of cohort and samples collected.

(B) CD4$^+$ and CD8$^+$ T cell responses to SARS-CoV-2 S, N, and M peptide pools in COVID-19 cases and suspected cases. Representative fluorescence-activated cell sorting (FACS) plots showing IFN-γ and TNF staining of CD4$^+$ or CD8$^+$ T cell populations; background staining values are shown in brackets. Frequencies of IFN-γ^+, TNF$^+$, MIP-1β^+, or CD107a$^+$ within the CD4$^+$ or CD8$^+$ T cells, with background staining subtracted in COVID-19 cases (n = 3, 2 time points each) and suspected cases (n = 4); data are shown as mean with SD. Statistical significance was determined with Mann-Whitney test.

(C) FACS plots showing IFN-γ staining of CD4$^+$ or CD8$^+$ T cell populations from COVID-19 case CA2 V1 and V2 after stimulation with S, N, and M peptide pools; the number of IFN-γ^+ cells are shown. Paired frequencies of IFN-γ^+CD4$^+$ and CD8$^+$ T cells for S, N, and M peptide pools (right).

(D) FACS plots of CD8$^+$ IFN-γ/TNF staining after stimulation with individual N-derived SARS-CoV-2 peptides (N_{66}, N_{105}, N_{257}, N_{219}, and N_{222}) and FACS plots showing CD8$^+$ T cell staining with B7/SARS-CoV-2 tetramers (B7/N_{66}, B7/N_{105}, B7/N_{257}) on expanded cells. Frequency of IFN-γ^+CD8$^+$ or tetramer$^+$CD8$^+$ T cells are shown.

See also Table S1 and Figure S3.



(legend on next page)

subdominant B7/N_{257}, A2/S_{269} (Habel et al., 2020), and A24/S_{1208} (Ferretti et al., 2020). After validating tetramers in peptide-expanded T cell lines (as shown in Figure 1D), further *ex vivo* tetramer validation experiments were performed with direct *ex vivo* dual-tetramer staining of the immunodominant B7/N_{105} tetramers conjugated to phycoerythrin (PE) and allophycocyanin (APC) fluorophores, as well as dual TAME with B7/N_{105} tetramer PE and an irrelevant B7/EBV tetramer (EBNA-$3_{379-387}$, RPPIFIRRL) conjugated to APC (Figures S4A and S4B). Following TAME (Figure 2), $CD8^+$ T cells specific for the immunodominant B7/N_{105} epitope could be readily detected *ex vivo* in all COVID-19 patients (Figure 2A; Figure S4C) at a mean frequency of 6.88×10^{-4} (n = 11; Figure 2D), with the B7/N_{105}+$CD8^+$ T cells being easily detected without enrichment (Figure 2A). B7/N_{105}-specific $CD8^+$ T cell pools in COVID-19 patients were numerically immunodominant when compared to 3 subdominant SARS-CoV-2-specific $CD8^+$ T cell populations directed at B7/N_{257}, A2/S_{269}, and A24/S_{1208} epitopes (by 38.03-, 21.54-, and 8.92-fold respectively; $p < 0.05$; Figure 2D).

The frequency of B7/N_{105}-specific $CD8^+$ T cells in COVID-19 patients was significantly higher than that in adult (mean 3.00×10^{-5}; p = 0.0017) and elderly (mean 6.76×10^{-5}; p = 0.0023) pre-pandemic PBMC samples (Figures 2B and 2D), suggesting clonal expansion after SARS-CoV-2 infection. The values for pre-pandemic children's tonsil samples (mean 2.76×10^{-4}) and elderly PBMCs (mean 6.76×10^{-5}) were variable, with some elderly individuals showing a decline in the magnitude of B7/N_{105}-specific $CD8^+$ T cells, most likely reflecting a loss of tetramer-positive $CD8^+$ T cells with age (Nguyen et al., 2018). Moreover, the magnitude of the immunodominant B7/N_{105} in combined pre-pandemic adult and elderly PBMCs (mean 4.64×10^{-5}) was higher than that for the subdominant B7/N_{257} (mean 1.52×10^{-6}; $p < 0.0001$), the previously described A2/S_{269} frequencies (Habel et al., 2020) (mean 1.65×10^{-6}; p = 0.0022), and A24/S_{1208}, although not statistically significant (mean 9.5×10^{-6}; p = 0.2484 Mann-U) (Figure 2D), suggesting that the immunodominance of B7/N_{105}-specific $CD8^+$ T cell responses in COVID-19 reflects higher precursor frequencies in unexposed individuals. Although the frequency of SARS-CoV-2-specific B7/N_{105} tetramer-positive $CD8^+$ T cells in children's pre-pandemic tonsils (mean 2.76×10^{-4}) appeared higher than that found in matched PBMCs (mean 2.5×10^{-5}) (Figure 2C), this difference was not statistically significant (p = 0.125). Analysis of spleen and lung samples did not show any robust distinct populations of B7/N_{105}-specific $CD8^+$ T cells in pre-pandemic tissues (Figure S4D). It thus seems that the immunodominant B7/N_{105}-specific $CD8^+$ T cells are present in high precursor frequencies in pre-pandemic adult PBMCs and increase by 14.82-fold during SARS-CoV-2 infection in the peripheral blood.

SARS-CoV-2 tetramer-positive $CD8^+$ T cells in pre-pandemic individuals show predominantly naive phenotype

The activation profiles of B7/N_{105}-specific $CD8^+$ T cells tested by tetramer staining directly *ex vivo* from COVID-19 patients and pre-pandemic donors across different ages were assessed by CD27, CD45RA, and CD95 staining to determine the prevalence of the naive (T_{Naive}) ($CD27^+CD45RA^+CD95^-$), stem cell memory (T_{SCM}) ($CD27^+CD45RA^+CD95^+$), central memory (T_{CM})-like ($CD27^+CD45RA^-$), effector memory (T_{EM})-like ($CD27^-CD45RA^-$), and effector memory CD45RA (T_{EMRA}) ($CD27^-CD45RA^+$) subsets (Figure 3). As expected, COVID-19 donors displayed the lowest proportion of T_{Naive} B7/N_{105}+$CD8^+$ T cells (mean of 10%) and instead had the highest proportion of T_{CM}-like B7/N_{105}+$CD8^+$ T cells (mean of 61%). Conversely, pre-pandemic children and adult B7/N_{105}+$CD8^+$ T cells were predominantly of the T_{Naive} phenotype ($p < 0.0001$ for both age groups in comparison with COVID-19 samples) and had minimal activation profiles across all the T cell subsets tested (Figure 3C), indicating that these B7/N_{105}+$CD8^+$ T cells constitute a naive precursor pool rather than a pre-existing memory population from exposure to other coronaviruses or pathogens. Although cross-reactive memory T cell responses between human coronaviruses and SARS-CoV-2 have been described after stimulation of pre-pandemic PBMCs with peptide megapools and readouts by IFN-γ production, these T cells usually express distinct memory markers (Le Bert et al., 2020; Peng et al., 2006), indicating that SARS-CoV-2 tetramer-reactive T cells in our pre-pandemic samples are truly naive. Both T_{Naive} and T_{CM}-like subsets varied across different elderly individuals, suggesting that B7/N_{105}+$CD8^+$ T cells in some elderly individuals were either previously activated by cross-reactive peptides or underwent age-related dysregulated homeostatic proliferation, as commonly observed with age (LeMaoult et al., 2000; Messaoudi et al., 2006; Valkenburg et al., 2012).

Naive profiles in pre-pandemic subdominant B7/N_{257}-, A2/S_{269}-, and A24/S_{1208}-specific $CD8^+$ T cells largely reflected those found for the immunodominant pre-pandemic B7/N_{105}-specific $CD8^+$ T cells (Figure 3C). In COVID-19 patients, activation profiles of subdominant B7/N_{257}-specific $CD8^+$ T cells were similar to those in immunodominant B7/N_{105}-specific $CD8^+$ T cells and consisted largely of T_{CM} phenotypes. In

Figure 2. High precursor frequency for immunodominant B7/N_{105}-specific $CD8^+$ but not subdominant B7/N_{257}-, A2/S_{269}-, and A24/S_{1208}-specific $CD8^+$ T cells

(A and B) B7/N_{105}-, B7/N_{257}-, A2/S_{269}-, and A24/S_{1208}-specific $CD8^+$ T cells were identified directly *ex vivo* from COVID-19 PBMCs, as well as from healthy pre-pandemic PBMCs and tonsils by tetramer magnetic enrichment. Representative FACS plots of enriched and unenriched B7/N_{105}-, B7/N_{257}-, A2/S_{269}-, and A24/S_{1208}-specific $CD8^+$ T cells from (A) acute and convalescent COVID-19 donors and (B) pre-pandemic children (PBMCs and tonsils), adult, and elderly donors. Pre-pandemic A2/S_{269} donors from Habel et al. [2020].

(C) B7/N_{105}-specific $CD8^+$ T cell precursor frequencies were calculated for matched children's PBMC and tonsil samples, with statistical significance analyzed by Wilcoxin test.

(D) $CD8^+$ precursor frequencies were calculated for B7/N_{105}-, B7/N_{257}-, A2/S_{269}-, and A24/S_{1208}-specific $CD8^+$ T cells enriched from PBMCs and tonsils. Dots represent individual donors; data are shown as mean. Donors with undetectable precursor frequencies are included on the graph to show the number of donors tested; these donors were not included in statistical analyses. Statistical significance was determined with Dunn's multiple comparison test unless indicated otherwise.

See also Figure S4.



(legend on next page)

contrast, A2/S_{269}-specific CD8$^+$ and A24/S_{1208}-specific CD8$^+$ T cells in COVID-19 were more skewed toward T_{Naive}, T_{SCM}, and/or T_{EMRA} phenotypes.

Frequencies and phenotypes of SARS-CoV-2-specific B7/$N_{105}$$^+$CD8$^+$ T cells remain largely stable in convalescent COVID-19 individuals

To assess whether the high numbers and T_{CM} phenotype of B7/N_{105}-specific CD8$^+$ T cells changed or remained stable over time, we longitudinally sampled HLA-B*07:02-expressing COVID-19 individuals from acute to convalescent time points for up to 270 days post-disease onset (n = 9 COVID-19 patients, 22 samples). The longitudinal frequencies of B7/N_{105}-specific CD8$^+$ T cells remained stable and relatively high, whereas the very low numbers of subdominant B7/N_{257}-specific CD8$^+$ T frequencies, many below the detection limit (<10 tetramer-positive-enriched events), did not expand over time (Figures 4A and 4C). Individual phenotypes were then tracked over time and across age (Figures 4B and 4C), which generally showed very stable populations of T_{CM}-like B7/N_{105}-specific CD8$^+$ T cells in most COVID-19 individuals, as well as in 1 individual with longitudinal B7/N_{257}-specific CD8$^+$ T cell responses (Figure 4B). However, T_{EMRA}-like populations increased over time in 4 individuals (CA6, 10, 11, and 13), 3 out of 4 being elderly donors (65 years and over), whereas T_{SCM} populations either increased or decreased in certain individuals. Overall, apart from some fluctuations in T_{SCM}- and T_{EMRA}-like populations, both the frequencies and T_{CM}-like phenotypes remained stable over time in convalescent individuals up to 270 days post-disease onset.

CD8$^+$ T cells specific for B7/N_{105} display diverse TCR$\alpha\beta$ repertoire and promiscuous TCRα-TCRβ pairing

The nature of the TCR repertoire can affect CD8$^+$ T cell immunodominance, functionality, and protection (Messaoudi et al., 2002; Ndhlovu et al., 2015; Price et al., 2009). We therefore defined the molecular signatures underpinning the immunodominant B7/$N_{105}$$^+$CD8$^+$ T cell response. We dissected TCR$\alpha\beta$ clonal composition and diversity with direct *ex vivo* tetramer staining and human single-cell TCR$\alpha\beta$ multiplex RT-PCR, as described previously (Nguyen et al., 2017a; Valkenburg et al., 2016). Here, we showed *ex vivo* dissection of TCR$\alpha\beta$ repertoires for immunodominant B7/N_{105}-specific CD8$^+$ T cells in PBMCs from 4 HLA-B*07:02-expressing COVID-19 patients and 4 pre-pandemic PBMC samples. We examined a total of 264 B7/N_{105}-specific CD8$^+$ T cells TCR$\alpha\beta$ pairs in total (Figure 5; Table S2).

TCR$\alpha\beta$ sequences were first analyzed for the overall TCR$\alpha\beta$ diversity on a per-individual basis (Figure 5A). Segments shown by the same color represent TCR$\alpha\beta$ clonotypes with the same V segment usage but different CDR3 sequences. The B7/N_{105}-specific CD8$^+$ TCR$\alpha\beta$ repertoire of each COVID-19 patient was generally diverse, with the presence of 1 to 3 largely expanded TCR$\alpha\beta$ clonotypes and a number (mean of 19 per donor) of smaller TCR$\alpha\beta$ clonotypes. Clone B (TRBV6-6/TRAV17) was detected in 2 COVID-19 patients (Figures 5A and 5E), thus representing a shared TCR$\alpha\beta$ clonotype for the B7/$N_{105}$$^+$CD8$^+$ repertoire. Apart from clone B, each donor had distinct usage of TRAV, TRBV, TRAJ, and TRBJ gene segments, with no common gene features found across the COVID-19 patients and no common motifs within CDR3α and CDR3β sequences (Figure 5E; Table S2). Similarly, the pre-pandemic B7/N_{105}-specific CD8$^+$ repertoires were highly diverse between donors, with no predominant TCR$\alpha\beta$ V-J gene sharing between them (Figure 5B).

Lack of common TCR$\alpha\beta$ segment features was even more evident when we analyzed the TCR$\alpha\beta$ repertoire on a per-individual basis with circos plots (Figure 5C), with the color of the segment indicating TRBV gene usage (on the left), and the pairing with a specific TRAV segment depicted by the color of the outer arch (on the right). Again, our circos analysis revealed a remarkable level of diversity in TRAV and TRBV usage within the individual COVID-19 patients and across the donors for both COVID-19 and pre-pandemic, suggesting the plasticity of TCRα-TCRβ pairings. Across all COVID-19 and pre-pandemic TCRs, only 1 COVID-19 patient (CA4, 2 clonotypes) shared the same TRAV-TRBV pairing (TRBV29-1/TRAV13-1) with 1 pre-pandemic individual (PP24, 8 clonotypes), with very similar CDR3$\alpha\beta$ regions (Figure 5E). To further investigate TCRα-TCRβ pairings, we represented TRAV versus TRBV gene usage in a bubble plot for COVID-19 patients. We found 26 different TRBVs capable of pairing across 31 distinct TRAVs gene segments (Figure 5D). This shows that the TCR$\alpha\beta$ diversity in B7/N_{105}-specific CD8$^+$ T cells arises from distinct TCR$\alpha\beta$ gene segment usage and TRAV-TRBV pairings both across and within the donors and not from being associated with any CDR3α or CDR3β motifs across different donors. These data suggest that promiscuity in TCRα-TCRβ pairing and CDR3α-CDR3β sequences (rather than stringent requirements for TCR$\alpha\beta$ common features) underlie high naive precursor frequency within immunodominant B7/N_{105}-specific CD8$^+$ T cells, capable of expansion after SARS-CoV-2 infection.

A2/$S_{269}$$^+$CD8$^+$ TCR$\alpha\beta$ repertoire contains common TRAV/TRAJ motifs

Because CD8$^+$ T cells directed at SARS-CoV-2-specific A2/S_{269} represent subdominant and suboptimal T cell specificity in COVID-19 (Habel et al., 2020), we also investigated *ex vivo*

Figure 3. *Ex vivo* activation profiles of SARS-CoV-2-specific CD8$^+$ T cells in COVID-19 and pre-pandemic donors

(A and B) Representative FACS plots of B7/N_{105}-, B7/N_{257}-, A2/S_{269}-, and A24/S_{1208}-specific CD8$^+$ T cells from (A) acute and convalescent COVID-19 donors and (B) pre-pandemic children (PBMCs and tonsils), adult, and elderly donors showing T_{Naive} (CD27$^+$CD45RA$^+$CD95$^-$), T_{SCM} (CD27$^+$CD45RA$^+$CD95$^+$), T_{CM}-like (CD27$^+$CD45RA$^-$), T_{EM}-like (CD27$^-$CD45RA$^-$), and T_{EMRA} (CD27$^-$CD45RA$^+$) subsets. To account for donor variability in the phenotype markers and day-to-day variations in flow cytometry settings (e.g., laser power, compensation, calibration), phenotype gates were first selected on the larger parent CD8$^+$ T cell population for each individual before applying the gates to the smaller tetramer$^+$ population. The same gates were used across time points from the same individual if they were acquired on the same day.

(C) Stacked plots display the proportion of each phenotype subset within the B7/N_{105}-, B7/N_{257}-, A2/S_{269}-, and A24/S_{1208}-specific CD8$^+$ T cells. Only donors above the detection limit ($\geq$10 tetramer-positive-enriched events) were included for analysis; mean with SD is shown, and statistical significance was determined with Tukey's multiple comparisons test.



(legend on next page)

TCRαβ repertoires within A2/S_{269}-specific CD8+ T cells and how it differs to that of immunodominant B7/N_{105}-specific CD8+ T cells. As we and others previously reported (Habel et al., 2020; Peng et al., 2020), A2/S_{269}-specific CD8+ T cells detected *ex vivo* with tetramers represented a small but distinct population in COVID-19 patients (n = 5; Figure 3A). The TCRαβ repertoire displayed a considerable level of diversity by both circos and bubble plots (Figures 6A–6C), although common TRBV (43% of total 175 TCRs: TRBV2 at 11%, TRBV7-9 at 13%, TRBV20-1 at 20%), TRBJ (68% of total TCRs: TRBJ2-2 at 59%, TRBJ2-7 at 9%), TRAV (32% of total TCRs: TRAV12-1 at 23%, TRAV12-2 at 3%, TRAV14/DV4 at 6%), and TRAJ (24% of total TCRs: TRAJ43 at 18%, TRAJ30 at 6%) gene segments were found across different COVID-19 patients (Figures 6A and 6B; Table S3). More importantly, 2 key TCRα motifs within the CDR3α loop were found across the COVID-19 patients (Figure 6D). These included (1) TRAV12-1/TRAJ43 CVVN*XXX*DMRF motif (where *X* denotes any amino) found across all COVID-19 patients (16% of total TCR repertoire), paired with different prominent TRBV segments, and (2) TRAV12-2/TRAJ30 CAVN*X*DDKIIF pairing with TRBV7-9 across 4 donors (except CA6) (3.4% of TCR repertoire), as also recently reported by Shomuradova and colleagues (Shomuradova et al., 2020). These findings suggest that, in contrast to the B7/N_{105}-specific CD8+ repertoire with no common motif and lack of shared TRBV, TRBJ, TRAV, or TRAJ gene segment usage, TCRαβ clonotypes within the subdominant A2/S_{269}-specific CD8+ T cells had dominant TRBV, TRBJ, TRAV, or TRAJ gene segment usage across the donors and well-defined CDR3α motifs, suggesting more rigid requirements for TCRαβ clones capable of recognizing A2/S_{269} epitopes. Such lack of TCRαβ plasticity most likely results in such low naive precursor frequency (Habel et al., 2020).

CD8+ T cells specific for B7/N_{105} display high TCR diversity within pre-pandemic PBMCs

To determine the extent of TCR diversity between pre-pandemic B7/N_{105}, COVID-19 B7/N_{105}, and A2/S_{269} TCR repertoires, an independent analysis was performed with the TCRdist framework (Dash et al., 2017) across equivalent numbers of TCRαβ pairs per group to calculate diversity scores for single alpha and beta chains and paired TCRαβ clonotypes (Figure 7A; Table S4). As observed in our earlier analyses, the A2/S_{269} TCR repertoire (paired TCRdiv = 147.9) was less diverse than both pre-pandemic and COVID-19 B7/N_{105} repertoires, in which diversity was mainly driven by the beta chain. Pre-pandemic B7/N_{105}-specific TCRs were extremely diverse (paired TCRdiv = 730.4) and then narrowed after primary COVID-19 infection with different individuals (paired TCRdiv = 299.9), although the latter were still considered highly diverse. To contextualize the COVID-19 TCR diversity with other well-established acute (influenza A) and chronic viral infections (EBV and human cytomegalovirus [CMV]), the TCR diversity against the B7/N_{105} epitope was reminiscent of the relatively diverse TCR repertoires against the chronic and immunodominant A2/CMV-pp65$_{495-503}$ epitope. Independent analysis of the common CDR3 motifs was also conducted with TCRdist (Dash et al., 2017) to generate highly significant alpha and beta amino acid motifs for A2/S_{269} and B7/N_{105} TCRs (Figure 7B; Figure S5). Similar to our initial analysis (Figure 6D), COVID-19 A2/S_{269} TCR repertoire generated 2 dominant alpha motifs (TRAV12-2/12-1-TRAJ43/30), where the gene pairing of TRAV12-1 with TRAJ43 was highly significant ($p < 2.3E{-}07$, Figure S6). In comparison, COVID-19 B7/N_{105} TCR repertoire encompassed several alpha and beta chain motifs which, surprisingly, did not overlap with the pre-pandemic B7/N_{105} motifs.

The probability of generating (P_{gen}) TCR alpha and beta chains were then calculated with TCRdist, which correlated with the number of insertions and deletions within the CDR3 region (Figure 7C). Within the TCR alpha chain, P_{gen} values were similar for COVID-19 and well-established IAV, EBV, and CMV epitopes. The probability of generating beta chains in the B7/N_{105} groups was comparable between pre-pandemic and COVID-19, but both COVID-19 and pre-pandemic B7/N_{105}'s P_{gen} were significantly lower than those of A2/S_{269} (p_{adj} = 0.0012 and 0.0435, respectively) but similar to the A2/CMV repertoire. The lower beta P_{gen} values for B7/N_{105} were supported by both B7/N_{105} groups having significantly more beta N-insertions than A2/S_{269}; however, lower numbers of N deletions were only significantly observed for the COVID-19 B7/N_{105} TCR repertoire, but not for pre-pandemic B7/N_{105} or A2/S_{269}. Taken together, the lower probability of generating B7/N_{105} TCRs, by way of more insertions, reflects the extreme nature in diversity for both pre-pandemic and COVID-19 B7/N_{105} TCR repertoires.

DISCUSSION

Our study deciphered the most immunodominant CD8+ T cell response known to date in COVID-19, the B7/N_{105}+CD8+ T cell population. Our direct *ex vivo* approach, without any *in vitro* manipulations, revealed high precursor frequencies of B7/N_{105}-specific CD8+ T cells in COVID-19 patients ($\sim 6.88 \times 10^{-4}$), comparable to the magnitude of a well-established influenza-specific A2/$M1_{58}$-specific CD8+ T cell memory population (3.04×10^{-4}). High precursor frequencies were also detected in pre-pandemic adult and elderly PBMCs (3.00×10^{-5} and 6.76×10^{-5}, respectively), much higher than the precursor frequencies previously observed for naive CD8+ T cells directed toward HLA-A*02:01-restricted NY-ESO-$1_{1157-1165}$, WT$1_{126-134}$, HIV Gag p1_{777-85}, HCV Core$_{132-140}$, and CMV pp65 antigens (between 0.6×10^{-6} to 5.3×10^{-6}) in cancer-free and seronegative individuals (Alanio et al., 2010; Nguyen et al., 2017b). It was thus quite surprising that these B7/N_{105}-specific CD8+ T cells in pre-pandemic samples mainly displayed a naive phenotype, indicating a lack of previous cross-reactive exposures. Because the SARS-CoV-2-derived $N_{105-113}$ peptide SPRWYFYYL displays a close amino acid (aa) homology with the corresponding peptide LPRWYFYYL derived from N in the globally distributed

Figure 4. Tracking longitudinal COVID-19 B7/CD8+ T cell responses up to day 270 post disease onset

(A) TAME-enriched precursor frequencies of B7/N_{105}-specific CD8+ and B7/N_{257}-specific CD8+ T cells from each individual with multiple time points.

(B) Stacked bar graphs of each individual phenotype profiles of each donor across age.

(C) Representative FACS plots of donors' longitudinal B7/N_{105}-specific CD8+ T cell responses in terms of TAME-enriched (i) tetramer and (ii) phenotype profiles.



E

B7/N_{105}	TRBV	TRBJ	CDR3β	TRAV	TRAJ	CDR3α	COVID-19 CA12	COVID-19 CA13	COVID-19 CA2	COVID-19 CA4	Pre-pandemic PP18	Pre-pandemic PP14	Pre-pandemic PP24	Pre-pandemic PP27
Clone A	9	2-1	CASSVSGGAYNEQFF	3	31	CAVRDYNNARLMF	26 (72%)							
Clone B	6-6	2-7	CASRQLAGFYEQYF	17	57	CATDAGPEKLVF	1 (3%)	21 (66%)						
Clone C	27	2-4	CASNPLAGEFTAKNIQYF	10	31	CVVNGRDARLMF				9 (23%)				
	29-1	2-3	CSVDALLGAYTQYF	13-1	20	CAALPSADYKLSF			2 (5%)					
	29-1	2-7	CSVVPLAGPYEQYF	13-1	44	CAALAGTASKLTF							8 (26%)	
	29-1	2-7	CSVVPLMGGYEQYF	13-1	44	CACLTGTASKLTF				2 (5%)				
	29-1	2-7	CSVVPLAGPYEQYF	ND	ND	ND							2 (6%)	
Clone D	28	2-5	CASSSLTGQSQETQYF	8-4	5	CVGRDTGRRALTF			5 (13%)					
	7-2	1-1	CASRGGGTEAFF	ND	ND	ND			4 (10%)					
	19	1-2	CASSTLGTADKLNYGYTF	9-2	23	CALSVGNQGGKLIF			4 (10%)					
	9	2-3	CASSPTDNF	13-2	49	CADPNTGNQFYF								3 (10%)
	ND	ND	ND	13-2	49	CADPNTGNQFYF								26 (84%)
	9	2-1	CASSARDF	19	54	CALSEIQGAQKLVF						1 (3%)		
	12-3	2-2	CASSAGLAGANTGELFF	13-2	16	CAENQRFSDGQKLLF					1 (4%)			
	20-1	2-1	CSARGGFRSGGGTDEQFF	14/DV4	31	CAMREGRSARLMF		3 (9%)						
	20-1	2-1	CSARRGLNEQFF	14/DV4	20	CAMREGYSNDYKLSF						1 (3%)		
	5-4	2-4	CASSLETGRNIQYF	1-2	35	WAIGFGNVLHC				2 (5%)				
	2	2-7	CASSGLNDRFYEQYF	4	22	CLVGVPFSGSARQLTF					1 (4%)			
	6-1	2-7	CASSDRTGRRNEQYF	4	10	CLVAAPGNKLTF					1 (4%)			
	7-3	2-5	CASSLGTGAQETQYF	4	10	CLVATILTGGGNKLTF						1 (3%)		
						Other singletons	9 (25%)	8 (25%)	25 (63%)	26 (67%)	21 (86%)	28 (90%)	21 (68%)	2 (6%)
						Total	**36**	**32**	**40**	**39**	**24**	**31**	**31**	**31**

Figure 5. Diverse TCRαβ repertoire and promiscuous TCRα-TCRβ pairing within B7/N_{105}-specific $CD8^+$ T cells

(A and B) B7/N_{105}-specific $CD8^+$ T cells were enriched by TAME and then single-cell sorted for TCRαβ analysis. Pie charts of TRBV and TRAV gene usage in B7/$N_{105}$$^+CD8^+$ T cells in (A) COVID-19 (n = 4) and (B) pre-pandemic donors (n = 4). All COVID-19 patients were from convalescent samples with one exception, where

(legend continued on next page)

coronavirus strains HCoV-OC43 and HCoV-HKU1, there is potential for cross-reactive CD8+ T cell responses, which was notably observed in all 4 donors tested by Ferretti et al.'s study via genome-wide epitope screening technology and the secretion of granzyme B (Ferretti et al., 2020; Schulien et al., 2021). However, the overall conclusion was that the COVID-19 CD8+ T cell response was not significantly shaped by pre-existing immunity to endemic coronaviruses. However, because 100% of the pediatric and 81.3% of adult pre-pandemic donors in our study had a prototypical naive (and not even T_{SCM}) B7/N_{105}-specific CD8+ T cell phenotype directly *ex vivo*, this suggests that either the HCoV-OC43/HKU1 peptide is not presented on the infected cell surface (for example due to different processing of the peptide within the cell), the SARS-CoV-2-derived $N_{105–113}$ peptide is not cross-reactive with the corresponding N-derived peptides originating from other human coronaviruses, or our pre-pandemic adult and pediatric donors were not exposed to those circulating coronaviruses. Although we cannot exclude that these CD8+ T cells are naive antigen-experienced T cells that express a naive CD45RA+CD27−CD95− phenotype, our previous study indicated that the SARS-CoV2 A2/S_{269}-specific CD8+ T cells with naive CD45RA+CD27+CD95− phenotype could not respond to the peptide stimulation (Habel et al., 2020). These data are in line with previous phenotypical analysis of human coronavirus-specific T cells which do not express a naive phenotype (Le Bert et al., 2020; Peng et al., 2006), indicating that infection with human coronaviruses might not induce SARS-CoV-2 B7/$N_{105–113}$-specific T cells. We have not found effector and/or memory SARS-CoV-2 tetramer-positive CD8+ T cells in lungs or spleens from pre-pandemic donors, in contrast to readily detected memory influenza tetramer-positive CD8+ T cells across different epitopes found at these anatomical sites in our previous studies (Koutsakos et al., 2019; Sant et al., 2018).

Both the magnitude and phenotype of B7/N_{105}-specific CD8+ T cells were highly variable in the pre-pandemic elderly. Reduced magnitude of B7/N_{105}-specific CD8+ T cells in elderly individuals corresponds with published reports providing clear evidence for a loss of tetramer-positive CD8+ T cells as well as naive CD8+ T cell precursors with aging (Nguyen et al., 2018; Valkenburg et al., 2012). Although B7/N_{105}-specific CD8+ T cells within 4 elderly donors mainly had a naive phenotype, 3 donors had a high prevalence of T_{EMRA} (75%) and T_{CM}-like (37%–73%) subsets. This could be due to either priming with cross-reactive peptides derived from circulating coronaviruses occurring sequentially with age or SARS-CoV-2 CD8+ T cells undergoing age-related dysregulated homeostatic proliferation, as commonly observed with age and CMV seropositivity (LeMaoult et al., 2000; Messaoudi et al., 2006; Valkenburg et al., 2012; Wertheimer et al., 2014). The high frequency of T_{EMRA}-phenotype T cells observed in PP27 could be a result of age-related CD45RA upregulation observed previously in CMV-specific CD8+ T cells (Griffiths et al., 2013). It is, however, unclear whether this upregulation also occurs in antigen-specific CD8+ T cells in acute infection in contrast to constant exposure to antigens derived from persistent infections such as CMV, given that persistent infections can induce different memory phenotypes (Appay et al., 2002).

Because our TCRαβ analysis of the B7/N_{105}-specific CD8+ T cells obtained from the pre-pandemic elderly individual (PP27) with the high-frequency T_{EMRA} population showed a highly clonal TCRαβ repertoire, atypical of what we observed in other COVID-19 and pre-pandemic individuals, this suggested that the clonal B7/N_{105}-specific CD8+ T_{EMRA} population in this elderly individual represented a highly proliferating non-COVID-19-specific CD8+ T cell population. Whether or not the frequencies of SARS-CoV-2 tetramer-positive CD8+ T cells within adult tonsils are higher than those in adult blood will require future investigation. From our previous study, we found higher levels of influenza-specific CD8+ T cells in healthy adult tonsils than in unmatched healthy adult blood (Koutsakos et al., 2019).

Our analyses of longitudinal COVID-19 samples for B7/N_{105}+CD8+ T cell populations demonstrated the maintenance of predominant T_{CM}-like phenotypes into the long-term memory (up to d270 for some patients) after disease onset, similar to what we observed in patients hospitalized with H7N9 in Shanghai (Wang et al., 2015). Our findings are in agreement with studies showing that SARS-CoV-specific memory T cells persist into long-term memory for at least 6 to 11 years (Peng et al., 2006; Tang et al., 2011). However, it should be noted that distinct memory populations can be established after infection with different viruses (Appay et al., 2002) or even across different epitope-specific CD8+ T cells, as exemplified by our recent study (Habel et al., 2020) showing mainly T_{SCM}/naive phenotypes within A2/S_{269}+CD8+ T cells during convalescence.

Ex vivo TCRαβ analyses for the remaining COVID-19 patients and pre-pandemic samples across all ages revealed that a diverse TCRαβ repertoire and promiscuity in TCRα-TCRβ pairing could underlie such high naive precursor frequencies of B7/N_{105}-specific CD8+ T cells. The importance of TCRαβ repertoire diversity on disease outcome was previously reported (LeMaoult et al., 2000) in mice, macaques, and humans (Messaoudi et al., 2002; Chen et al., 2012; Price et al., 2009). Generally, a diverse TCRαβ repertoire provides a greater scope for selection of TCRαβ clonotypes with high peptide-MHC-I avidity. CD8+ T cells with diverse TCR repertoires can generate broadly protective responses and are often capable of recognizing both the wild-type virus and newly emerging mutants. Our single-cell *ex vivo* TCRαβ analysis, including independent analysis with the TCRdist framework, demonstrated higher TCRαβ diversity within immunodominant B7/N_{105}-specific CD8+ T cells with variable usage of TRAV, TRBV, TRAJ, and TRBJ gene segments. Furthermore, no common gene features and no common motifs

5 out of 36 TCR clonotypes for Donor CA12 were from the acute time point. Segments shown by the same color represent TCRαβ clonotypes with the same V segment usage but different CDR3 sequences.

(C) Circos plots of TRBV and TRAV clonotype pairings; left arch and segment color indicate TRBV usage, and right outer arch color depicts TRAV usage.

(D) Bubble plot showing the distribution (number of donors and frequency) of TRBV/TRAV gene usage in COVID-19 patients.

(E) Dominant clonotypes identified in HLA-B*07:02 donors specific to B7/N_{105}+CD8+ T cells. ND, not determined.

See also Table S2.



D

						Acute		Convalescent			
TRBV	**TRBJ**	**CDR3β**	**TRAV**	**TRAJ**	**CDR3α**	**CA16**	**CA14**	**CA14**	**CA19**	**CA18**	**CA2**
TRBV12-3	TRBJ2-2	CAXXXXNTGELFF	TRAV12-1	TRAJ43	CVVNXXXDMRF						6 (11%)
Other			TRAV12-1	TRAJ43	CVVNXXXDMRF	1 (33%)	4 (7%)	6 (16%)	1 (8%)	1 (17%)	2 (4%)
TRBV2	TRBJ2-2	CASXXXX(n)TGELFF	TRAV12-1	TRAJ43	CVVNXX(n)NDMRF		3 (5%)		1 (8%)		3 (5%)
TRBV2	TRBJ2-2	CAXXXXX(n)TGELFF	Other			1 (33%)	1 (2%)	2 (5%)			5 (9%)
TRBV20-1	TRBJ2-2	CSAXXX(n)NTGELFF	Other				7 (12%)	3 (8%)		1 (17%)	2 (4%)
TRBV7-9	TRBJ1-1	CASSXDIXAFF	TRAV12-2	TRAJ30	CAVNRDDKIIF		1 (2%)	1 (3%)			1 (2%)
TRBV7-9	TRBJ2-1	CASSFDIAEFF	TRAV12-2	TRAJ30	CAVNQDDKIIF		1 (2%)				
TRBV7-9	TRBJ2-7	CASSPDIEQYF	TRAV12-2	TRAJ30	CAVNRDDKIIF	1 (33%)				1 (17%)	
					Other singletons	0	43 (72%)	25 (68%)	10 (83%)	3 (50%)	38 (67%)
					Total	3	60	37	12	6	57

Figure 6. Common TRAV/TRAJ motifs within suboptimal A2/S_{269}-specific $CD8^+$ TCRαβ repertoire

A2/$S_{269}$$^+$$CD8^+$ T cells from COVID-19 PBMCs were identified *ex vivo* and enriched by TAME before single-cell sorting for TCRαβ analysis.

(A) Pie charts of TRBV and TRAV gene usage in A2/$S_{269}$$^+$$CD8^+$ T cells in acute and convalescent COVID-19 donors. Segments shown by the same color represent TCRαβ clonotypes with the same V segment usage but different CDR3 sequences.

(B) Circos plots of TRBV and TRAV clonotype pairings; left arch and segment color indicates TRBV usage, and right outer arch color depicts TRAV usage. Ac, acute; F_{up}, follow-up convalescent sample.

(C) Bubble plot showing the distribution (number of donors and frequency) of TRBV/TRAV gene usage.

(D) Dominant clonotypes identified in HLA-A*02:01 donors specific to A2/$S_{269}$$^+$$CD8^+$ T cells. X denotes any amino acid, and (n) denotes any number of additional amino acids.

See also Table S3.

within CDR3α and CDR3β sequences were observed across the donors. Such TCRαβ repertoire diversity, combined with the promiscuity of TCRα-TCRβ pairing, might reflect a high degree of TCRαβ plasticity to recognize the immunodominant B7/N_{105} epitope. Consequently, this plasticity could lead to the generation of a large and diverse pool of naive TCRαβ precursors

A

Epitope	Group	Donors	TCRαβ pairs	TCRαβ clones	TCRdiv-α	TCRdiv-β	TCRdiv-αβ
A2/S_{269}	COVID-19	4	43	35	34.8	101.0	147.9
B7/N_{105}	COVID-19	4	42	25	282.3	291	299.9
B7/N_{105}	Pre-pandemic	4	43	37	935.7	322.9	730.4



(legend on next page)

and, hence, high precursor frequency of B7/N_{105}-specific CD8$^+$ T cells. When it comes to immunodominance hierarchies, both naive precursor frequency and antigen dose play a key role (La Gruta et al., 2006). Thus, a high naive precursor frequency in pre-pandemic samples could underlie highly immunodominant B7/$N_{105}$$^+$CD8$^+$ T cell responses in COVID-19 patients during acute disease and convalescence. Future crystallography studies of ternary N_{105} peptide in the context of HLA-B*07:02 and TCR$\alpha\beta$s are needed to provide key insights into promiscuous TCR$\alpha\beta$ recognition of the B7/N_{105} epitope, as well as the inclusion of more nucleocapsid-derived epitopes and tetramers for further TCR repertoire studies. The TCR$\alpha\beta$ repertoire within the dominant B7/N_{105}-specific CD8$^+$ T cells contrasted those of subdominant SARS-CoV-2-specific A2/S_{269}-specific CD8$^+$ T cells containing clear CDR3α motifs and TRAV usage (as shown by our study and the recent report by Shomuradova et al., [2020]). The latter reflected numerous previously analyzed TCR$\alpha\beta$ repertoires of viral-specific CD8$^+$ T cell populations in mice and humans, characterized by biased usage of TCR gene segments (Kedzierska and Koutsakos, 2020).

Overall, our study suggests that high precursor frequency and plasticity of TCRα-TCRβ pairing underpin the immunodominance of SARS-CoV-2-specific B7/$N_{105}$$^+$CD8$^+$ T cell responses. As both the immunodominant B7/N_{105} and subdominant B7/N_{257} SARS-CoV-2-specific epitopes encompass nucleocapsid-derived peptides, infection with SARS-CoV-2 clearly leads to robust CD8$^+$ T cell immunity in HLA-B*07:02 individuals. Better understanding of T cells directed toward immunodominant epitopes and their origins provides important insights into the rational design of next-generation vaccine strategies to optimize long-lasting CD8$^+$ T cell immunity.

Limitations of the study

We recognize that our pre-pandemic and COVID-19 donors originate from 1 country and thus do not represent the global population. This might be especially relevant when CD8$^+$ T cell responses toward the circulating human coronavirus strains are assessed. Cross-reactivity of CD8$^+$ T cell responses against different SARS-CoV-2 variants was not addressed in the current manuscript and is of interest for future studies. The number of pre-pandemic children's samples was relatively small to perform in-depth analyses. Further *ex vivo* examination of tetramer-positive CD8$^+$ T cells in SARS-CoV-2-infected children would be of a great interest to understand SARS-CoV-2-specific CD8$^+$ T cells responses in acute COVID-19 and convalescence.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
- METHOD DETAILS
  - Peptides and peptide-HLA class I tetramers
  - *Ex vivo* tetramer enrichment
  - TCR$\alpha\beta$ repertoire analysis
  - Phenotypic whole blood immune analyses
  - Detection of SARS-CoV-2 RBD- and Spike-reactive B cells
  - Intracellular cytokine staining (ICS)
  - SARS-CoV-2 RBD and Spike ELISA
  - Microneutralisation assay
  - Cytokine analysis
- QUANTIFICATION AND STATISTICAL ANALYSIS
  - TCR statistical analysis
  - Statistical analysis

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.immuni.2021.04.009.

ACKNOWLEDGMENTS

We thank all the participants involved in the study, as well as Robyn Esterbauer, Hannah Kelly, Jane Batten, Helen Kent, and Kanta Subbarao for support with the cohorts and assays. We thank Jill Garlick, Janine Roney, Anne Paterson, and the research nurses at the Alfred Hospital. We acknowledge all DRASTIC (The use of cytokines as a preDictoR of disease Severity in criTically Ill Covid-patients) investigators from Austin Health and thank the participants involved. We thank Ana Copaescu for laboratory work and study coordination for the DRASTIC study. We thank Thomas Loudovaris and Stuart I. Mannering from St Vincent's Institute of Medical Research for access to spleen samples. This work was supported by the Clifford Craig Foundation to K.L.F. and K.K.; an NHMRC Leadership Investigator Grant to K.K. (1173871); an NHMRC Emerging Leadership Level 1 Investigator Grant to THON (1194036); an NHMRC program grant to D.L.D. (1132975); the Research Grants Council of the Hong Kong Special Administrative Region, China (T11-712/19-N) to K.K.; the Victorian government to S.J.K. and A.K.W.; an MRFF award (2002073) to

Figure 7. TCR repertoire diversity and distinct single-chain motifs within COVID-19 and pre-pandemic individuals

(A) Single alpha, beta, and paired TCRdiv diversity values between COVID-19 A2/S_{269}, B7/N_{105} and pre-pandemic (PP) B7/N_{105} repertoires. COVID-19 A2/S_{269} (43 out of 75) and B7/N_{105} TCRs (42 out of 82) were randomly down-sampled to obtain equivalent TCR pairs for comparison with the pre-pandemic B7/N_{105} group. The higher value indicates higher diversity.

(B) Enriched alpha and beta amino acid motifs in the CDR3 region were generated by TCRdist for all TCR pairs. Each TCR chain motif depicts the variable (left side) and joining (right side) gene frequencies, CDR3 amino acid sequences (middle), and inferred rearrangement structure (bottom bars colored by source region: light gray, V-region; dark gray, J-region; black, diversity [D]-region; red, insertions). Chi-square values greater than 50 were considered highly significant; values below 50 were borderline significant. The full set of motifs are shown in Figure S5.

(C) Probabilities of generation (Pgen; log10 transformed), and number of nucleotide insertions and deletions for all single alpha and beta chains, were generated with the TCRdist pipeline and contextualized with publicly available data from A2/EBV-BMLF1$_{280-288}$, A2/M1$_{58-66}$ (influenza A), and A2/CMV-pp65$_{495-503}$ TCR repertoires, which were not included in the statistical analysis. Statistical analysis between COVID-19 A2/S_{269}, B7/N_{105}, and B7/N_{105} pre-pandemic (PP) repertoires for variations in P_{gen}, insertions, and deletions are further described in the STAR Methods with linear mixed models. p values were adjusted (p_{adj}) for multiple testings with the Benjamini and Hochberg FDR method. Box plots represent the median (middle bar), 75% quantile (upper hinge), and 25% quantile (lower hinge), with whiskers extending 1.5 times the inter-quartile range.

See also Table S4, Figure S5, and Figure S6.

S.J.K. and A.K.W.; an MRFF award (1202445) to K.K.; an MRFF award (2005544) to K.K., S.J.K., J.A.J., and A.K.W.; an NHMRC program grant (1149990) to S.J.K.; an NHMRC project grant (1162760) to A.K.W.; and NIH contract CIVR-HRP (HHS-NIH-NIAID-BAA2018) to P.G.T. and K.K. A.K.W. is supported by an Emerging Leadership 1 Investigator Grant (1173433), J.A.J. by an NHMRC Early Career Fellowship (ECF) (1123673), D.L.D. by an NHMRC Principal Research Fellowship (1137285), and S.J.K. by an NHMRC Senior Principal Research Fellowship (1136322). C.E.S. has received funding from the European Union's Horizon 2020 research, innovation program under the Marie Skłodowska-Curie grant agreement (792532) and the Doherty Collaborative Seed Grant. J.R. is supported by an ARC Laureate fellowship. J.R.H. and W.Z. are supported by the Melbourne Research Scholarship from the University of Melbourne. L.H. is supported by the Melbourne International Research Scholarship (MIRS) and the Melbourne International Fee Remission Scholarship (MIFRS) from The University of Melbourne. J.C.C. and P.G.T. are supported by NIH NIAID (R01 AI136514-03) and ALSAC at St. Jude.

AUTHOR CONTRIBUTIONS

K.K. led the study. K.K., J.T., and J.R. supervised the study. K.K., J.T., J.R., T.H.O.N., L.C.R., J.P., B.Y.C., and L.K. designed the experiments. T.H.O.N., L.C.R., J.P., B.Y.C., L.H., L.K., P.C., H.T., J.R.H., W.Z., L.A., L.E., K.Y.M., J.A.J., K.W., F.L.M., and A.K.W. performed and analyzed experiments. F.A., F.K., N.A.M., and A.K.W. provided reagents. D.L.D., K.L.F., S.S., J.K., L.M.W., G.P.W., F.J., E.M., C.L.G., N.E.H., O.C.S., J.A.T., A.C.C., P.H., P.C., and S.J.K. recruited the patient cohorts. T.H.O.N., L.C.R., J.P., J.R., J.T., and K.K. provided intellectual input into the study design and data interpretation. T.H.O.N., L.C.R., C.E.S., J.C.C., and P.G.T. analyzed TCR sequences. T.H.O.N., L.C.R., and K.K. wrote the manuscript. All authors reviewed and approved the manuscript.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: November 24, 2020
Revised: February 23, 2021
Accepted: April 12, 2021
Published: April 15, 2021

REFERENCES

Alanio, C., Lemaitre, F., Law, H.K., Hasan, M., and Albert, M.L. (2010). Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies. Blood *115*, 3718–3725.

Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T.H.O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G.A., Jurczyszak, D., Polanco, J., et al. (2020). A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. *26*, 1033–1036.

Appay, V., Dunbar, P.R., Callan, M., Klenerman, P., Gillespie, G.M., Papagno, L., Ogg, G.S., King, A., Lechner, F., Spina, C.A., et al. (2002). Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. *8*, 379–385.

Bates, D., Mächler, M., Bolker, B., and Walker, S. (2014). Fitting Linear Mixed-Effects Models Usinglme4. J. Stat. Softw. *61*, https://doi.org/10.18637/jss.v067.i01.

Caly, L., Druce, J., Roberts, J., Bond, K., Tran, T., Kostecki, R., Yoga, Y., Naughton, W., Taiaroa, G., Seemann, T., et al. (2020). Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia. Med. J. Aust. *212*, 459–462.

Channappanavar, R., Fett, C., Zhao, J., Meyerholz, D.K., and Perlman, S. (2014). Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. J. Virol. *88*, 11034–11044.

Chen, H., Ndhlovu, Z.M., Liu, D., Porter, L.C., Fang, J.W., Darko, S., Brockman, M.A., Miura, T., Brumme, Z.L., Schneidewind, A., et al. (2012). TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat. Immunol. *13*, 691–700.

Clemens, E.B., Grant, E.J., Wang, Z., Gras, S., Tipping, P., Rossjohn, J., Miller, A., Tong, S.Y., and Kedzierska, K. (2016). Towards identification of immune and genetic correlates of severe influenza disease in Indigenous Australians. Immunol. Cell Biol. *94*, 367–377.

Dan, J.M., Mateus, J., Kato, Y., Hastie, K.M., Yu, E.D., Faliti, C.E., Grifoni, A., Ramirez, S.I., Haupt, S., Frazier, A., et al. (2021). Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science *371*, eabf4063.

Dash, P., Fiore-Gartland, A.J., Hertz, T., Wang, G.C., Sharma, S., Souquette, A., Crawford, J.C., Clemens, E.B., Nguyen, T.H.O., Kedzierska, K., et al. (2017). Quantifiable predictive features define epitope-specific T cell receptor repertoires. Nature *547*, 89–93, https://doi.org/10.1038/nature22383.

Ferretti, A.P., Kula, T., Wang, Y., Nguyen, D.M.V., Weinheimer, A., Dunlap, G.S., Xu, Q., Nabilsi, N., Perullo, C.R., Cristofaro, A.W., et al. (2020). Unbiased Screens Show $CD8^+$ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. Immunity *53*, 1095–1107.e3.

Gonzalez-Galarza, F.F., McCabe, A., Santos, E.J.M.D., Jones, J., Takeshita, L., Ortega-Rivera, N.D., Cid-Pavon, G.M.D., Ramsbottom, K., Ghattaoraya, G., Alfirevic, A., et al. (2020). Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools. Nucleic Acids Res. *48* (D1), D783–D788.

Griffiths, S.J., Riddell, N.E., Masters, J., Libri, V., Henson, S.M., Wertheimer, A., Wallace, D., Sims, S., Rivino, L., Larbi, A., et al. (2013). Age-associated increase of low-avidity cytomegalovirus-specific CD8+ T cells that re-express CD45RA. J. Immunol. *190*, 5363–5372.

Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings, S.A., Sutherland, A., Premkumar, L., Jadi, R.S., et al. (2020). Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell *181*, 1489–1501.e15, e1415.

Gu, Z., Gu, L., Eils, R., Schlesner, M., and Brors, B. (2014). circlize Implements and enhances circular visualization in R. Bioinformatics *30*, 2811–2812.

Habel, J.R., Nguyen, T.H.O., van de Sandt, C.E., Juno, J.A., Chaurasia, P., Wragg, K., Koutsakos, M., Hensen, L., Jia, X., Chua, B., et al. (2020). Suboptimal SARS-CoV-2-specific $CD8^+$ T cell response associated with the prominent HLA-A*02:01 phenotype. Proc. Natl. Acad. Sci. USA *117*, 24384–24391.

Juno, J.A., Tan, H.-X., Lee, W.S., Reynaldi, A., Kelly, H.G., Wragg, K., Esterbauer, R., Kent, H.E., Batten, C.J., Mordant, F.L., et al. (2020). Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat. Med. *26*, 1428–1434.

Kedzierska, K., and Koutsakos, M. (2020). The ABC of Major Histocompatibility Complexes and T Cell Receptors in Health and Disease. Viral Immunol. *33*, 160–178.

Koutsakos, M., Wheatley, A.K., Loh, L., Clemens, E.B., Sant, S., Nüssing, S., Fox, A., Chung, A.W., Laurie, K.L., Hurt, A.C., et al. (2018). Circulating T_{FH} cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity. Sci. Transl. Med. *10*, eaan8405.

Koutsakos, M., Illing, P.T., Nguyen, T.H.O., Mifsud, N.A., Crawford, J.C., Rizzetto, S., Eltahla, A.A., Clemens, E.B., Sant, S., Chua, B.Y., et al. (2019). Human $CD8^+$ T cell cross-reactivity across influenza A, B and C viruses. Nat. Immunol. *20*, 613–625.

Koutsakos, M., Rowntree, L.C., Hensen, L., Chua, B.Y., van de Sandt, C.E., Habel, J.R., Zhang, W., Jia, X., Kedzierski, L., Ashhurst, T.M., et al. (2021). Integrated immune dynamics define correlates of COVID-19 severity and antibody responses. Cell Rep Med *2*, 100208.

La Gruta, N.L., Kedzierska, K., Pang, K., Webby, R., Davenport, M., Chen, W., Turner, S.J., and Doherty, P.C. (2006). A virus-specific CD8+ T cell immunodominance hierarchy determined by antigen dose and precursor frequencies. Proc. Natl. Acad. Sci. USA *103*, 994–999.

Le Bert, N., Tan, A.T., Kunasegaran, K., Tham, C.Y.L., Hafezi, M., Chia, A., Chng, M.H.Y., Lin, M., Tan, N., Linster, M., Chia, W.N., Chen, M.I.C., Wang, L-F, Ooi, E.E., Kalimuddin, S., Tambyah, P.A., Low, J.G-H., Tan, Y-J., and Bertoletti, A. (2020). SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature *584*, 457–462.

LeMaoult, J., Messaoudi, I., Manavalan, J.S., Potvin, H., Nikolich-Zugich, D., Dyall, R., Szabo, P., Weksler, M.E., and Nikolich-Zugich, J. (2000). Age-related dysregulation in CD8 T cell homeostasis: kinetics of a diversity loss. J. Immunol. *165*, 2367–2373.

Messaoudi, I., Guevara Patiño, J.A., Dyall, R., LeMaoult, J., and Nikolich-Zugich, J. (2002). Direct link between mhc polymorphism, T cell avidity, and diversity in immune defense. Science *298*, 1797–1800.

Messaoudi, I., Warner, J., Nikolich-Zugich, D., Fischer, M., and Nikolich-Zugich, J. (2006). Molecular, cellular, and antigen requirements for development of age-associated T cell clonal expansions in vivo. J. Immunol. *176*, 301–308.

Ndhlovu, Z.M., Kamya, P., Mewalal, N., Kløverpris, H.N., Nkosi, T., Pretorius, K., Laher, F., Ogunshola, F., Chopera, D., Shekhar, K., et al. (2015). Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point. Immunity *43*, 591–604.

Nguyen, T.H., Bird, N.L., Grant, E.J., Miles, J.J., Thomas, P.G., Kotsimbos, T.C., Mifsud, N.A., and Kedzierska, K. (2017a). Maintenance of the EBV-specific $CD8^+$ TCR$\alpha\beta$ repertoire in immunosuppressed lung transplant recipients. Immunol. Cell Biol. *95*, 77–86.

Nguyen, T.H., Tan, A.C., Xiang, S.D., Goubier, A., Harland, K.L., Clemens, E.B., Plebanski, M., and Kedzierska, K. (2017b). Understanding $CD8^+$ T-cell responses toward the native and alternate HLA-A*02:01-restricted WT1 epitope. Clin. Transl. Immunology *6*, e134.

Nguyen, T.H.O., Sant, S., Bird, N.L., Grant, E.J., Clemens, E.B., Koutsakos, M., Valkenburg, S.A., Gras, S., Lappas, M., Jaworowski, A., et al. (2018). Perturbed $CD8^+$ T cell immunity across universal influenza epitopes in the elderly. J. Leukoc. Biol. *103*, 321–339.

Peng, H., Yang, L.T., Wang, L.Y., Li, J., Huang, J., Lu, Z.Q., Koup, R.A., Bailer, R.T., and Wu, C.Y. (2006). Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein in SARS-recovered patients. Virology *351*, 466–475.

Peng, Y., Mentzer, A.J., Liu, G., Yao, X., Yin, Z., Dong, D., Dejnirattisai, W., Rostron, T., Supasa, P., Liu, C., et al.; Oxford Immunology Network Covid-19 Response T cell Consortium; ISARIC4C Investigators (2020). Broad and strong memory $CD4^+$ and $CD8^+$ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat. Immunol. *21*, 1336–1345.

Price, D.A., Asher, T.E., Wilson, N.A., Nason, M.C., Brenchley, J.M., Metzler, I.S., Venturi, V., Gostick, E., Chattopadhyay, P.K., Roederer, M., et al. (2009). Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection. J. Exp. Med. *206*, 923–936.

Rowntree, L.C., Nguyen, T.H.O., Farenc, C., Halim, H., Hensen, L., Rossjohn, J., Kotsimbos, T.C., Purcell, A.W., Kedzierska, K., Gras, S., and Mifsud, N.A. (2020). A Shared TCR Bias toward an Immunogenic EBV Epitope Dominates in HLA-B*07:02-Expressing Individuals. J. Immunol. *205*, 1524–1534.

Sant, S., Grzelak, L., Wang, Z., Pizzolla, A., Koutsakos, M., Crowe, J., Loudovaris, T., Mannering, S.I., Westall, G.P., Wakim, L.M., et al. (2018). Single-Cell Approach to Influenza-Specific $CD8^+$ T Cell Receptor Repertoires Across Different Age Groups, Tissues, and Following Influenza Virus Infection. Front. Immunol. *9*, 1453.

Schulien, I., Kemming, J., Oberhardt, V., Wild, K., Seidel, L.M., Killmer, S., Sagar, Daul, F., Salvat Lago, M., Decker, A., et al. (2021). Characterization of pre-existing and induced SARS-CoV-2-specific $CD8^+$ T cells. Nat. Med. *27*, 78–85, https://doi.org/10.1038/s41591-020-01143-2.

Shomuradova, A.S., Vagida, M.S., Sheetikov, S.A., Zornikova, K.V., Kiryukhin, D., Titov, A., Peshkova, I.O., Khmelevskaya, A., Dianov, D.V., Malasheva, M., et al. (2020). SARS-CoV-2 epitopes are recognized by a public and diverse repertoire of human T cell receptors. Immunity *53*, 1245–1257.e5.

Stadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G.A., Tan, J., Bhavsar, D., Capuano, C., Kirkpatrick, E., et al. (2020). SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr. Protoc. Microbiol. *57*, e100.

Tang, F., Quan, Y., Xin, Z.T., Wrammert, J., Ma, M.J., Lv, H., Wang, T.B., Yang, H., Richardus, J.H., Liu, W., and Cao, W.C. (2011). Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J. Immunol. *186*, 7264–7268.

Thevarajan, I., Nguyen, T.H.O., Koutsakos, M., Druce, J., Caly, L., van de Sandt, C.E., Jia, X., Nicholson, S., Catton, M., Cowie, B., et al. (2020). Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat. Med. *26*, 453–455.

Valkenburg, S.A., Venturi, V., Dang, T.H., Bird, N.L., Doherty, P.C., Turner, S.J., Davenport, M.P., and Kedzierska, K. (2012). Early priming minimizes the age-related immune compromise of $CD8^+$ T cell diversity and function. PLoS Pathog. *8*, e1002544.

Valkenburg, S.A., Josephs, T.M., Clemens, E.B., Grant, E.J., Nguyen, T.H., Wang, G.C., Price, D.A., Miller, A., Tong, S.Y., Thomas, P.G., et al. (2016). Molecular basis for universal HLA-A*0201-restricted CD8+ T-cell immunity against influenza viruses. Proc. Natl. Acad. Sci. USA *113*, 4440–4445.

Wang, Z., Wan, Y., Qiu, C., Quiñones-Parra, S., Zhu, Z., Loh, L., Tian, D., Ren, Y., Hu, Y., Zhang, X., et al. (2015). Recovery from severe H7N9 disease is associated with diverse response mechanisms dominated by $CD8^+$ T cells. Nat. Commun. *6*, 6833, https://doi.org/10.1038/ncomms7833.

Wang, Z., Zhu, L., Nguyen, T.H.O., Wan, Y., Sant, S., Quiñones-Parra, S.M., Crawford, J.C., Eltahla, A.A., Rizzetto, S., Bull, R.A., et al. (2018). Clonally diverse $CD38^+HLA\text{-}DR^+CD8^+$ T cells persist during fatal H7N9 disease. Nat. Commun. *9*, 824.

Weiskopf, D., Schmitz, K.S., Raadsen, M.P., Grifoni, A., Okba, N.M.A., Endeman, H., van den Akker, J.P.C., Molenkamp, R., Koopmans, M.P.G., van Gorp, E.C.M., et al. (2020). Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci. Immunol. *5*, eabd2071.

Wertheimer, A.M., Bennett, M.S., Park, B., Uhrlaub, J.L., Martinez, C., Pulko, V., Currier, N.L., Nikolich-Žugich, D., Kaye, J., and Nikolich-Žugich, J. (2014). Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans. J. Immunol. *192*, 2143–2155.

Wickham, H. (2016). ggplot2: Elegant Graphics for Data Analysis (Springer-Verlag).

Zhao, J., Alshukairi, A.N., Baharoon, S.A., Ahmed, W.A., Bokhari, A.A., Nehdi, A.M., Layqah, L.A., Alghamdi, M.G., Al Gethamy, M.M., Dada, A.M., et al. (2017). Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. Sci. Immunol. *2*, eaan5393.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
CD71 M-A712 BV421	BD Biosciences	Cat#562995; RRID: AB_2737939
CD4 SK3 BV650	BD Biosciences	Cat#563875; RRID: AB_2744425
CD27 L128 BV711	BD Biosciences	Cat#563167; RRID: AB_2738042
CD38 HIT2 BV786	BD Biosciences	Cat#563964; RRID: AB_2738515
CCR7 150503 AF700	BD Biosciences	Cat#561143; RRID: AB_10562031
CD14 MΦP9 APC-H7	BD Biosciences	Cat#560180; RRID: AB_1645464
CD19 SJ25C1 APC-H7	BD Biosciences	Cat#560177; RRID: AB_1645470
CD45RA HI100 FITC	BD Biosciences	Cat#555488; RRID: AB_395879
CD8a SK1 PerCP-Cy5.5	BD PharMingen	Cat#565310; RRID: AB_2687497
CD95 DX2 PE-CF594	BD Biosciences	Cat#562395; RRID: AB_11153666
PD-1 EH12.1 PE-Cy7	BD Biosciences	Cat#561272; RRID: AB_10611585
CD3 OKT3 BV510	BioLegend	Cat#317332; RRID: AB_2561943
HLA-DR L243 BV605	BioLegend	Cat#307640; RRID: AB_2561913
CD69 FN50 BV421	BioLegend	Cat#310930; RRID: AB_2561909
CD103 Ber-ACT8 FITC	BioLegend	Cat#350203; RRID: AB_10642828
CD45RO UCHL1 PE-Cy7	Thermo Fisher Scientific	Cat#25-0457-41; RRID: AB_10717670
CD56 MEM-188 APC	BioLegend	Cat#304610; RRID: AB_314452
CD16 3G8 AF700	BioLegend	Cat#302026; RRID: AB_2278418
CD19 HIB19 BV570	BioLegend	Cat#302236; RRID: AB_2563606
CD3 UCHT1 PECF594	BD Biosciences	Cat#562280; RRID: AB_11153674
CD8a RPA-T8 BV421	BioLegend	Cat#301036; RRID: AB_10960142
Granzyme B GB11 AF700	BD Biosciences	Cat#560213; RRID: AB_1645453
Granzyme K G3H69 PerCP-eFluor710	Thermo Fisher Scientific	Cat#46-8897-42; RRID: AB_2573854
Granzyme M 4B2G4 eFluor660	Thermo Fisher Scientific	Cat#50-9774-42; RRID: AB_2574374
Perforin B-D48 Pe-Cy7	BioLegend	Cat#353316; RRID: AB_2571973
CD19 J4.119 ECD	Beckman Coulter	Cat#IM2708U; RRID: AB_130854
IgM G20-127 BUV395	BD Biosciences	Cat#563903; RRID: AB_2721269
CD21 B-ly4 BUV737	BD Biosciences	Cat#564437; RRID: AB_2738807
IgD IA6-2 PE-Cy7	BD Biosciences	Cat#561314; RRID: AB_10642457
IgG G18-145 BV786	BD Biosciences	Cat#564230; RRID: AB_2738684
Streptavidin BV510	BD Biosciences	Cat#563261; RRID: AB_2869477
CD20 2H7 APC-Cy7	BioLegend	Cat#302314; RRID: AB_314262
CD14 M5E2 BV510	BioLegend	Cat#301841; RRID: AB_2561379
CD8a RPA-T8 BV510	BioLegend	Cat#301048; RRID: AB_2561942
CD16 3G8 BV510	BioLegend	Cat#302048; RRID: AB_2562085
CD10 HI10a BV510	BioLegend	Cat#312220; RRID: AB_2563835
CD27 O323 BV605	BioLegend	Cat#302829; RRID: AB_11204431
IFN-γ RUO V450	BD Bioscience	Cat#560371; RRID: AB_1645594
TNF Mab11 AF700	BD Bioscience	Cat#557996; RRID: AB_396978
MIP-1b D21-1351 APC	BD Bioscience	Cat#560686; RRID: AB_1727565
CD107a eBioH4A3 ΩAF48	Thermo Fisher Scientific	Cat#53-1079-42; RRID: AB_2016657
Streptavidin PE	BD Biosciences	Cat#349023, RRID: AB_2868860
Streptavidin APC	BD Biosciences	Cat#349024, RRID: AB_2868861
Streptavidin PE	Thermo Fisher Scientific	Cat#S866

(*Continued on next page*)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
APC Conjugation Lightning-Link Kit	Abcam	Cat#ab201807
Peroxidase AffiniPure goat anti-human IgG, Fcγ fragment specific	Jackson ImmunoResearch	Cat#109-035-098; RRID: AB_2337586
Rat anti-human IgA mAb MT20, alkaline phosphate-conjugated	MabTech	Cat#3860-9A; RRID: AB_10736550
anti-human IgM mAb MT22, biotinylated	MabTech	Cat#3880-6-250
Bacterial and Virus Strains		
SARS-CoV-2 isolate CoV/Australia/VIC01/2020	Caly et al., 2020	N/A
Biological Samples		
Blood samples (peripheral blood mononuclear cells (PBMCs), serum and plasma samples) from COVID-19 patients and healthy control individuals	Alfred Hospital, Austin Health, The University of Melbourne, James Cook University, Australian Red Cross LifeBlood and Launceston General Hospital (Australia)	N/A
Tissue samples (tonsil, spleen and lung samples) from healthy control individuals	Launceston General Hospital, Alfred Hospital's Lung Tissue Biobank and DonateLife Victoria (Australia)	N/A
Chemicals, Peptides, and Recombinant Proteins		
AccuCheck Counting Beads	Thermo Fisher Scientific	Cat#PCB100
3,3¢,5,5¢-Tetramethylbenzidine (TMB) Liquid Substrate System for ELISA, peroxidase substrate	Sigma	Cat#T0440-1L
Alkaline phosphatase yellow (pNPP) liquid substrate for ELISA	Sigma	Cat#P7998-100ML
Pierce High Sensitivity Streptavidin-HRP	Thermo Fisher Scientific	Cat#21130
SARS-CoV-2 RBD protein	Amanat et al., 2020	N/A
SARS-CoV-2 RBD protein	Juno et al., 2020	N/A
SARS-CoV-2 Spike protein	Juno et al., 2020	N/A
PepTivator® SARS-CoV-2 Prot_S	Miltenyi Biotec	Cat#130-126-700
PepTivator® SARS-CoV-2 Prot_N	Miltenyi Biotec	Cat#130-126-698
PepTivator® SARS-CoV-2 Prot_M	Miltenyi Biotec	Cat#130-126-702
SARS-CoV-2 peptides - B7/N_{66-74} FPRGQGVPI; B7/$N_{105-113}$ SPRWYFYYL; B7/$N_{257-265}$ KPRQKRTAT; A2/$N_{219-227}$ LALLLLDRL; A2/$N_{222-230}$ LLLDRLNQL; A24/S_{1208} QYIKWPWYI	GenScript	N/A
HLA-B*07:02 and HLA-A*24:02 monomers with N_{105}, N_{257}, N_{66} (for HLA-B*07:02) or S_{1208} (for HLA-A*24:02) peptide	This paper	N/A
A2/S_{269} monomer (SARS-CoV-2, S_{269}, YLQPRTFLL)	Habel et al., 2020	N/A
B7/EBV monomer (EBNA-$3_{379-387}$, RPPIFIRRL)	Rowntree et al., 2020	N/A
Critical Commercial Assays		
eBioscience™ Foxp3/Transcription Factor Staining Buffer Set	Thermo Fisher Scientific	Cat#00-5521-00
LEGENDplex™ Human Inflammation Panel 1 kit	BioLegend	Cat#740809
Experimental Models: Cell Lines		
Vero C1008, African Green monkey kidney cells	ATCC	Cat#CRL-1586; Lot#3338237; RRID: CVCL_0574

(*Continued on next page*)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Software and Algorithms		
R v3.6.2	The Comprehensive R Archive Network	https://cran.r-project.org
Circlize R package	Gu et al., 2014	https://cran.r-project.org/package=circlize
ggplot R package	Wickham, 2016	https://ggplot2.tidyverse.org
TCRdist pipeline	Dash et al., 2017	https://github.com/phbradley/tcr-dist
lme4 R package	Bates et al., 2014	https://www.jstatsoft.org/article/view/v067i01/
FlowJo v10.5.3	FlowJo	https://www.flowjo.com
Prism v8.3.1 or v9.1.0	GraphPad	https://www.graphpad.com
BD FACS Diva v8.0.1	BD Biosciences	https://www.bdbiosciences.com/en-us/instruments/research-instruments/research-software/flow-cytometry-acquisition/facsdiva-software
Other		
Anti-PE MicroBeads	Miltenyi Biotec	Cat# 130-048-801, RRID: AB_244373
Anti-APC MicroBeads	Miltenyi Biotec	Cat# 130-090-855, RRID: AB_244367

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Katherine Kedzierska (kkedz@unimelb.edu.au).

Materials availability

This study did not generate new unique reagents.

Data and code availability

The published article includes all datasets generated or analyzed during the study.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

A total of 21 COVID-19 cases (CA) and 40 pre-pandemic (PP) subjects were recruited into this study (Table S1). The traveler cohort included 3 COVID-19 cases (CA1-3) at convalescence and 4 suspected cases (SU1-4). Acute and convalescent COVID-19 patients were recruited via the Alfred Hospital, Austin Hospital, University of Melbourne or James Cook University. Eight of the donors were admitted to hospital during their active infection (Table S1). Healthy pre-pandemic blood donors were recruited via the University of Melbourne or buffy packs obtained from the Australian Red Cross LifeBlood (West Melbourne, Australia) (Table S1). Healthy COVID-19-unexposed and pre-pandemic tonsils, spleens and lungs were also obtained. Matched tonsils and PBMCs were obtained from healthy individuals undergoing tonsillectomy (Launceston General Hospital, Tasmania, Australia), lung samples via the Alfred Hospital's Lung Tissue Biobank, while spleens were provided by DonateLife Victoria. Donors were HLA typed by VTIS (Melbourne, Australia). Peripheral blood was collected in heparinized tubes and peripheral blood monocular cells (PBMCs) were isolated via Ficoll-Paque separation. Single cell suspensions were isolated from tissues as previously described (Habel et al., 2020; Koutsakos et al., 2018).

Experiments conformed to the Declaration of Helsinki Principles and the Australian National Health and Medical Research Council Code of Practice. Written informed consents were obtained from all blood donors prior to the study. Lung and spleen tissues were obtained from deceased organ donors after written informed consents from the next of kin. Written informed consents were obtained from participants' parental or guardians for underage tonsil tissue donors. The study was approved by the Alfred Hospital (#280/14), Austin Health (HREC/63201/Austin-2020); the University of Melbourne (#2057366.1, #2056901.1, #2056689, #2056761, #1442952, #1955465, and #1443389), the Australian Red Cross Lifeblood (ID 2015#8), the Tasmanian Health and Medical (ID H0017479) and the James Cook University (H7886) Human Research Ethics Committees.

METHOD DETAILS

Peptides and peptide-HLA class I tetramers

Overlapping synthetic peptides spanning the SARS-CoV-2 Nucleocapsid (N) and Membrane (M) proteins, and the immunogenic regions of Spike (S) were purchased from Miltenyi Biotec and reconstituted in 80% DMSO. SARS-CoV-2 peptides shown to bind

HLA-B*07:02, HLA-A*02:01 and HLA-A*24:02 (B7/N_{66-74} FPRGQGVPI; B7/$N_{105-113}$ SPRWYFYYL; B7/$N_{257-265}$ KPRQKRTAT; A2/$N_{219-227}$ LALLLLDRL; A2/$N_{222-230}$ LLLDRLNQL and A24/S_{1208} QYIKWPWYI) were purchased from GenScript and reconstituted in DMSO. Tetramers were generated from soluble, biotinylated HLA-B*07:02 or HLA-A*24:02 monomers. Briefly, HLA α-heavy chain with C-terminal BirA biotinylation motif and β2-microglobulin were expressed and purified as inclusion bodies in *E. coli*, solubilized in 6M Guanidine HCl and refolded with either N_{105}, N_{257}, N_{66} (for HLA-B*07:02) or S_{1208} (for HLA-A*24:02) peptide, in buffer containing 50mM Tris pH8, 3M urea, 0.4M Arginine, 2mM oxidised Glutathione, 20mM Glutathione, 2mM EDTA, 10mM PMSF and cOmplete protease inhibitor (Roche). Following dialysis in 10mM Tris, HLA monomers were purified via DEAE and HiTrapQ ion exchange chromatography, and biotinylated with BirA ligase in 50mM Bicine pH 8.3, 10mM ATP, 10mM magnesium acetate and 100μm d-biotin. Following S200 gel permeation chromatography fully biotinylated HLA monomers were stored at -80°C and conjugated to fluorescently-labeled streptavidin (SA), PE-SA or APC-SA (BD Biosciences) at an 8:1 monomer to SA molar ratio to form pMHC-I tetramers. The A2/S_{269} (SARS-CoV-2, S_{269}, YLQPRTFLL) and B7/EBV (EBNA-$3_{379-387}$, RPPIFIRRL) tetramers were generated as previously described (Habel et al., 2020) (Rowntree et al., 2020).

Ex vivo tetramer enrichment

PBMCs, tonsils and spleens (7-50x10^6) were stained with B7/N_{105}-PE, B7/N_{257}-APC, A2/S_{269}-PE or A24/S_{1208}-APC tetramers at room temperature for 1 h in MACS buffer (PBS with 0.5% BSA and 2 mM EDTA). Cells were then incubated with anti-PE and anti-APC microbeads (Miltenyi) and tetramer$^+$ cells were enriched using magnetic separation (Nguyen et al., 2017b; Valkenburg et al., 2016). Lymphocytes were stained with anti-CD71-BV421 (#562995), anti-CD4-BV650 (#563875), anti-CD27-BV711 (#563167), anti-CD38-BV786 (#563964), anti-CCR7-AF700 (#561143), anti-CD14-APC-H7 (#560180), anti-CD19-APC-H7 (#560177), anti-CD45RA-FITC (#555488), anti-CD8-PerCP-Cy5.5 (#565310), anti-CD95-PE-CF594 (#562395), anti-PD1-PE-Cy7 (#561272) (BD Biosciences), anti-CD3-BV510 (#317332), anti-HLA-DR-BV605 (#307640) (BioLegend, San Diego, CA, USA) and Live/Dead near-infrared (#L10119, Invitrogen) stain for 30 min, washed, resuspended in MACS buffer and analyzed by flow cytometry. Lung cells were stained with tetramer for 1 h then cell surface stained using a modified panel to include anti-CD69-BV421 (#310930), anti-CD103-FITC (#350203) (BioLegend) and anti-CD45RO-PE-Cy7 (#25-0457-41, Thermo Fisher Scientific). In some experiments, cells were fixed with 1% PFA and washed before acquiring on a LSRII Fortessa (BD) or single cell sorted using the FACSAriaIII (BD) for TCR analyses. FCS files were analyzed using FlowJo v10 software.

TCR$\alpha\beta$ repertoire analysis

Tetramer$^+$ CD8$^+$ T cells were single-cell sorted into empty 96-well Twin.tec PCR plates (Eppendorf, Hamburg, Germany), centrifuged then stored at -80°C. Multiplex-nested RT-PCR amplification of paired CDR3a and CDR3b regions were performed as described (Nguyen et al., 2017b; Valkenburg et al., 2016). TCR sequences were analyzed using IMGT/V-QUEST. Data visualization was performed in R using packages for circular layout (Gu et al., 2014) and graphics generation (Wickham, 2016).

Phenotypic whole blood immune analyses

Fresh whole blood was used to analyze immune cell populations using three human antibody panels for enumerating immune cell activation (monocytes and T/B/NK/$\gamma\delta$ cells), T_{FH} and ASC cell activation, and cytotoxicity profiles of T cell's expressing intracellular granzymes (A, B, K and M) and perforin, as previously described (Thevarajan et al., 2020). PBMCs were stained, red blood cell lysed, then fixed in 1% PFA, or intracellularly stained using the eBioscience^{TM} Foxp3/Transcription Factor Staining Buffer Set (Thermo Fisher Scientific, Carlsbad, CA, USA) (Thevarajan et al., 2020). Samples were acquired on a BD LSRII Fortessa and analyzed using FlowJo v10 software.

Detection of SARS-CoV-2 RBD- and Spike-reactive B cells

PBMCs were stained with SARS-CoV-2 Spike and RBD probes, as previously described (Juno et al., 2020). Probes were generated by sequential addition of streptavidin-phycoerythrin (PE) (Thermo Fisher Scientific) to trimeric S protein biotinylated using recombinant Bir-A (Avidity), while SARS-CoV-2 RBD was labeled to APC using an APC Conjugation Lightning-Link Kit (Abcam). PBMCs were surface stained with Aqua viability dye (Thermo Fisher) and monoclonal antibodies against CD19-ECD (#IM2708U, Beckman Coulter), IgM BUV395 (#563903), CD21 BUV737 (#564437), IgD PE-Cy7 (#561314), IgG BV786 (#564230), streptavidin-BV510 (#563261) (BD Biosciences), CD20 APC-Cy7 (#302314), CD14 BV510 (#301841), CD3 BV510 (#317332), CD8a BV510 (#301048), CD16 BV510 (#302048), CD10 BV510 (#312220) and CD27 BV605 (#302829) (BioLegend). Cells were washed, fixed with 1% formaldehyde and acquired on a BD LSRII Fortessa.

Intracellular cytokine staining (ICS)

PBMCs were stimulated with 0.6 nmol of overlapping SARS-CoV-2 peptides for 10 days in RF-10 medium (+10U/mL IL-2) (Koutsakos et al., 2019). On d10, cells were stimulated with peptides for 5-6 h in the presence of GolgiPlug and GolgiStop (BD Biosciences) plus 10U/mL IL-2, and SARS-CoV-2-reactive T cells were quantified using anti-IFN-γ-V450 (#560371), anti-TNF-AF700 (#557996), anti-MIP-1b-APC (#560686) (BD Biosciences), and anti-CD107a-AF488 (#53-1079-42, Thermo Fisher Scientific) in an ICS assay as previously described (Clemens et al., 2016).

SARS-CoV-2 RBD and Spike ELISA

RBD- and Spike-specific ELISA for detection of IgM, IgG and IgA antibodies was performed as described (Amanat et al., 2020; Stadlbauer et al., 2020), with some modifications: Nunc MaxiSorp flat bottom 96-well plates (Thermo Fisher Scientific) were used for antigen coating, blocking with PBS (containing w/v 1% BSA) and serial dilutions performed in PBS (containing v/v 0.05% Tween and w/v 0.5% BSA). For detection of IgG and IgA, peroxidase-conjugated goat anti-human IgG (Fcγ fragment specific; Jackson ImmunoResearch) or alkaline phosphate-conjugated rat anti-human IgA (mAb MT20; MabTech) was used and developed with TMB (Sigma) substrate for IgG or pNPP (Sigma) for IgA. For IgM, biotinylated mAb MT22 and peroxidase-conjugated streptavidin (Pierce; Thermo Fisher Scientific) was used. Peroxidase reactions were stopped using 1M H_3PO_4 and plates read on a Multiskan plate reader (Labsystems). Inter- and intra-experimental measurements were normalized using a positive control plasma from a COVID-19 patient run on each plate. Endpoint titers were determined by interpolation from a sigmodial curve fit (all R-squared values > 0.95; GraphPad Prism 8) as the reciprocal dilution of plasma that produced > 15% (for IgA and IgG) or > 30% (for IgM) absorbance of the positive control at a 1:31.6 (IgG and IgM) or 1:10 dilution (IgA). Seroconvertion was defined when titers were above the mean titer (plus 2 standard deviations) of healthy non-COVID-19 donors.

Microneutralisation assay

Microneutralisation activity of serum samples was assessed as previously described (Juno et al., 2020). SARS-CoV-2 isolate CoV/Australia/VIC01/2020 (Caly et al., 2020) was propagated in Vero cells and stored at −80°C. Sera were heat-inactivated at 56°C for 30 min and serially diluted. Residual virus infectivity in the serum/virus mixtures was assessed in quadruplicate wells of Vero cells incubated in serum-free media containing 1 μg/mL of TPCK trypsin at 37°C and 5% CO_2. Viral cytopathic effect was read on day 5. The neutralising antibody titer was calculated using the Reed–Muench method, as described (Juno et al., 2020).

Cytokine analysis

Patients' plasma was diluted 1:2 for measuring IL-1β, IFN-α2, IFNγ, TNFα, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23 and IL-33 using the LEGENDplex Human Inflammation Panel 1 kit, as per manufacturer's instructions (BioLegend).

QUANTIFICATION AND STATISTICAL ANALYSIS

TCR statistical analysis

Single-chain alpha and beta TCR sequences were independently parsed and analyzed using the TCRdist pipeline to detect statistically significant amino acid motifs and to model CDR3 insertions, deletions, and probabilities of generation (P_{gen}) (Dash et al., 2017). To test for variations in P_{gen}, insertions, and deletions across epitope specificities, we used linear mixed models (Bates et al., 2014) with the number of sequences per subject per epitope included as a covariate and subject included as a random effect in order to control for unintentional differences in sequencing effort and non-independence of the data across subjects, respectively. Log10 of P_{gen} was modeled using a Gaussian distribution, whereas insertions and deletions were analyzed using a generalized model for the negative binomial distribution. P values were adjusted (p_{adj}) for multiple testing using the Benjamini & Hochberg FDR method. We also used the TCRdist framework on a subset of the data to characterize repertoire diversity using TCRdiv, which was contextualized using publicly available data from A2/EBV-BMLF1$_{280\text{-}288}$, A2/M1$_{58\text{-}66}$ (influenza A), and A2/CMV-pp65$_{495\text{-}503}$ repertoires. For this analysis, we only considered cells that had functional, paired alpha and beta sequences, and we randomly down-sampled repertoires such that each were derived from an equivalent number of donors and had an equivalent number of TCRs for comparison (i.e., A2/S_{269}, B7/N_{105} COVID-19, A2/EBV, A2/M1 and A2/CMV). The subsampled and full repertoires are detailed in Table S4.

Statistical analysis

Statistical significance of nonparametric datasets (two-tailed) were determined using GraphPad Prism v9 software. Mann-Whitney (unpaired) and Wilcoxin (paired) tests were used for comparisons between two groups. Kruskal-Wallis (unmatched) test with Dunn's multiple comparisons was used to compare more than two groups. Tukey's multiple comparison test compared row means between more than two groups.

Immunity, Volume *54*

Supplemental information

$CD8^+$ T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor frequency and TCR promiscuity

Thi H.O. Nguyen, Louise C. Rowntree, Jan Petersen, Brendon Y. Chua, Luca Hensen, Lukasz Kedzierski, Carolien E. van de Sandt, Priyanka Chaurasia, Hyon-Xhi Tan, Jennifer R. Habel, Wuji Zhang, Lilith F. Allen, Linda Earnest, Kai Yan Mak, Jennifer A. Juno, Kathleen Wragg, Francesca L. Mordant, Fatima Amanat, Florian Krammer, Nicole A. Mifsud, Denise L. Doolan, Katie L. Flanagan, Sabrina Sonda, Jasveen Kaur, Linda M. Wakim, Glen P. Westall, Fiona James, Effie Mouhtouris, Claire L. Gordon, Natasha E. Holmes, Olivia C. Smibert, Jason A. Trubiano, Allen C. Cheng, Peter Harcourt, Patrick Clifton, Jeremy Chase Crawford, Paul G. Thomas, Adam K. Wheatley, Stephen J. Kent, Jamie Rossjohn, Joseph Torresi, and Katherine Kedzierska



Figure S1. COVID-19 traveller cohort, SARS-CoV-2-reactive antibody and B cell signatures. (A) ELISA titration curves (top) against the SARS-CoV-2 RBD and Spike proteins for IgG, IgM and IgA in COVID-19 cases (CA, n=3, 2 time points each), suspected cases (SU, n=4) and pre-pandemic healthy donors (n=8). Dotted line indicates the cut off for end-point titer determination. End-point titers (bottom) of SARS-CoV-2 RBD and Spike antibodies where the dotted line indicates the seroconversion threshold. Statistical significance was determined with Kruskal-Wallis and Dunn's multiple comparisons test. (B) Gating strategy for

SARS-CoV-2-specific B cells. B cells were gated based on FSC/SSC, singlets, live cells with exclusion for T cell/NK cell/monocyte lineage markers, then expression of CD19, and gated as IgD^{-}, $IgM^{+/-}$, $IgG^{+/-}$ and analysed for binding to SARS-CoV-2 probes, with expression of CD21/CD27. (C) Co-staining of class-switched B cells ($CD19^{+}IgD^{-}$) with RBD and Spike probes. Microneutralization titres are bracketed and shown alongside the donor codes. Frequencies of $Spike^{+}$, RBD^{+} and $Spike^{+}RBD^{+}$ B cells as a proportion of $CD19^{+}IgD^{-}$ B cells in PBMCs from COVID-19 cases (n=3, 2 time points each) and suspected cases (n=4); data are shown as median with IQR. Statistical significance was determined with Mann-Whitney test. (D) Isotype distribution (left) and memory B cell phenotypes (right) of $Spike^{+}$, RBD^{+} and $Spike^{+}RBD^{+}$ $CD19^{+}IgD^{-}$ B cells; data are shown as mean with SD. Statistical significance was determined with Tukey's multiple comparisons test. Related to Figure 1.



Figure S2. Lack of immune cell activation in traveller cohort at convalescence. (A) Representative FACS plots of activated CD38$^+$ NK cells, activated CD38$^+$HLA-DR$^+$ γδ, CD8$^+$ and CD4$^+$ T cells, as well as activated CD38$^+$CD27$^+$ ASC, ICOS$^+$PD-1$^+$ Tfh and monocytes in a COVID-19 case. Proportion of activated immune cells (left) and monotype subsets (right) in COVID-19 cases (n=3, 2 time points each) and suspected cases (n=4); data are shown as mean with SD. (B) Representative FACS plots of CD8$^+$ T cells expressing different cytotoxic molecules (Granzyme A, B, K, and M and perforin) in a COVID-19 case. Proportion of cytotoxic CD8$^+$ and CD4$^+$ T cells in COVID-19 cases (n=3, 1 time point for CA1, 2 time points

for CA2, CA3) and suspected cases (n=3); data are shown as mean with SD. T cells were gated based on FSC/SSC, singlets, $CD3^+$ T cells with exclusion for B cell/monocyte markers, then gated as $CD4^+$ or $CD8^+$ and analyzed for expression of granzyme A, B, K and M and perforin. (C) Total (left) and individual (right) levels across 13 cytokines in COVID-19 cases (n=3, 2 time points each), suspected cases (n=4) and healthy donors (n=8); data are shown as mean with SD and median with IQR, respectively. Statistical significance was determined with Kruskal-Wallis and Dunn's multiple comparisons test. Related to Figure 1.



Figure S3. Gating strategies for CD4$^+$ and CD8$^+$ T cell responses to SARS-CoV-2 overlapping peptide pools. (A) ICS gating strategy for intracellular IFN-γ, TNF, MIP-1β and CD107a after PBMCs were stimulated for 10 days with SARS-CoV-2 overlapping peptide pools. (B) Gating strategy after day 10-cultured CD8$^+$ T cells were dissected with individual peptides and assessed by ICS or by tetramer staining. Related to Figure 1.



Figure S4. B7/N$_{105}$$^{+}$CD8^{+} tetramer validation and staining in spleen and lungs. (A) FACS plots showing direct *ex vivo* dual-tetramer staining of the immunodominant B7/N$_{105}$ tetramer conjugated to PE and APC fluorophores in a COVID-19 and pre-pandemic donor. (B) TAME-enriched tetramer populations using B7/N$_{105}$ tetramer-PE and an irrelevant B7/EBV-tetramer (EBNA-3$_{379-387}$, RPPIFIRRL) conjugated to APC, representing 2 out of 4 experiments. Cells were gated on the total CD8^{+} T cell population. (C) Gating strategy of enriched tetramer^{+} cells and phenotype populations. (D) B7/N$_{105}$ tetramer staining of adult spleens following TAME enrichment (showing 2 out of 6 experiments) and direct tetramer staining of lung cells (non-

enriched) from 3 donors as concatenated FACS plots. Spleen and lungs were gated on $CD8^+$ T cells. Related to Figure 2 and Figure 3.

TCR-α

TCR-β

A2/S_{269} COVID-19



A2_S269 A #clones=58
chi-sq: 326.6
motif: ^...n..d.v
match-: 13 22.4%
match+: 14 24.1%
expect: 0.480
enrich: 27.1

A2_S269 A #clones=58
chi-sq: 322.6
motif: ^..VNk.....$
match-: 14 24.1%
match+: 19 32.8%
expect: 0.560
enrich: 25.0

A2_S269 B #clones=118
chi-sq: 1560.2
motif: ^.a..d.nsa.Lf
match-: 20 16.9%
match+: 25 21.2%
expect: 0.240
enrich: 83.3

A2_S269 B #clones=118
chi-sq: 1526.5
motif: ^.A....Ns.E.F
match-: 44 37.3%
match+: 46 39.0%
expect: 1.200
enrich: 36.7

A2_S269 B #clones=118
chi-sq: 552.2
motif: ^...a..v...F$
match-: 12 10.2%
match+: 12 10.2%
expect: 0.120
enrich: 100.0

A2_S269 B #clones=118
chi-sq: 212.9
motif: ^..Ak.a...Ns
match-: 8 6.8%
match+: 8 6.8%
expect: 0.280
enrich: 28.6



A2_S269 B #clones=118
chi-sq: 144.4
motif: a..QNT
match-: 8 6.8%
match+: 9 7.6%
expect: 0.400
enrich: 20.0

A2_S269 B #clones=118
chi-sq: 57.6
motif: S..D..A
match-: 8 6.8%
match+: 14 11.9%
expect: 0.880
enrich: 9.1

B7/N_{105} COVID-19



B7_N105pan A #clones=46
chi-sq: 56.2
motif: vG.Q
match-: 4 8.7%
match+: 4 8.7%
expect: 0.080
enrich: 50.0

B7_N105pan A #clones=46
chi-sq: 56.2
motif: ^....GP
match-: 4 8.7%
match+: 4 8.7%
expect: 0.242
enrich: 16.5



B7_N105pan A #clones=46
chi-sq: 56.2
motif: Da..d
match-: 4 8.7%
match+: 4 8.7%
expect: 0.160
enrich: 25.0



B7_N105pan B #clones=70
chi-sq: 240.2
motif: ^..s..LTa
match-: 8 11.4%
match+: 8 11.4%
expect: 0.240
enrich: 33.3



B7_N105pan B #clones=70
chi-sq: 82.3
motif: ^....aL
match-: 15 21.4%
match+: 15 21.4%
expect: 2.040
enrich: 7.4



B7_N105pan B #clones=70
chi-sq: 79.6
motif: P.G.E
match-: 5 7.1%
match+: 6 8.6%
expect: 0.280
enrich: 17.9

B7_N105pan B #clones=70
chi-sq: 78.4
motif: v...P.a
match-: 6 8.6%
match+: 6 8.6%
expect: 0.400
enrich: 15.0



B7_N105pan B #clones=70
chi-sq: 56.2
motif: aP....P
match-: 4 5.7%
match+: 4 5.7%
expect: 0.200
enrich: 20.0



B7_N105pan B #clones=70
chi-sq: 56.2
motif: L..A.T
match-: 4 5.7%
match+: 4 5.7%
expect: 0.080
enrich: 50.0



B7_N105pan B #clones=70
chi-sq: 42.3
motif: D.v...Y
match-: 4 5.7%
match+: 4 5.7%
expect: 0.320
enrich: 12.5

B7_N105pan B #clones=70
chi-sq: 33.8
motif: a..T..R
match-: 6 8.6%
match+: 6 8.6%
expect: 0.800
enrich: 7.5

B7/N_{105} PP

B7_N105pre A #clones=50
chi-sq: 30.2
motif: sV....N
match-: 3 6.0%
match+: 3 6.0%
expect: 0.040
enrich: 75.0



B7_N105pre B #clones=58
chi-sq: 68.4
motif: A...LA.G
match-: 5 8.6%
match+: 5 8.6%
expect: 0.320
enrich: 15.6

Figure S5. TCRdist analysis of alpha and beta motifs for COVID-19 epitopes. Enriched alpha and beta amino acid motifs in the CDR3 region were generated by TCRdist for all TCR pairs. Each TCR chain motif depicts the variable (left side) and joining (right side) gene frequencies, CDR3 amino acid sequences (middle), and inferred rearrangement structure (bottom bars coloured by source region: light grey = V-region, dark grey = J-region, black = diversity (D)-region, red = insertions). Chi-squared values greater than 50 were considered highly significant, values below 50 were borderline significant. Related to Figure 7.



Figure S6. Significant TRAV12-1 to AJ43 gene pairing for the A2/S269 epitope. Gene segment usage and pairing landscapes are shown for the dominant A2/S269 TCR motif. Each clonotype is assigned the same vertical length irrespective of clonotype size. Each vertical stack reflects the V (left) and J (right) gene segment usage and pairing is shown by curved connecting lines. Genes are ranked in colour by the frequency distribution with red being the highest frequency, followed by green, dark blue, aqua, magenta, black and thereafter. Enrichment or depletion of gene usage is indicated by up or down arrows respectively where 1 arrowhead correlates to a 2-fold increase or decrease. Related to Figure 7.

Supplementary Tables

Table S1. Donor demographics and clinical data. Related to Figure 1.

Donor	Age	Sex	Specimen	Cohort	Days post disease onset				Location during disease	Oxygen	HLA-A	HLA-B
					Acute	Visit 1	Visit 2	Visit 3				
CA1	24	M	Heparinized blood	COVID-19 Case	-	5*	9*	-	Asymptomatic/home	No	01:01, 32:01	08:01, 14:01
CA2	21	M	Heparinized blood	COVID-19 Case	-	~90#	~160#	-	Overseas	No	**02:01**, 11:01	**07:02**, 55:01
CA3	19	M	Heparinized blood	COVID-19 Case	-	92	162	-	Overseas	No	1:01	08:01, 52:01
CA4	32	F	Heparinized blood	COVID-19 Case	-	45	-	-	Home	No	03:01, 11:01	**07:02**, 50:01
CA5	49	F	Heparinized blood	COVID-19 Case	-	47	208	-	Home	No	02:01, 03:01	**07:02**, 55:01
CA6	52	M	Heparinized blood	COVID-19 Case	-	41	81	142	Home	No	02:01, **24:02**	**07:02**, 40:01
CA7	57	F	Heparinized blood	COVID-19 Case	16	108	-	-	Ward	No	01:01, 02:01	**07:02**, 38:01
CA8	58	F	Heparinized blood	COVID-19 Case	7	74	-	-	Ward	Nasal prong	02:01, 24:02	**07:02**
CA9	59	M	Heparinized blood	COVID-19 Case	-	69	216	-	Home	No	01:01, 02:01	**07:02**, 08:01
CA10	65	M	Heparinized blood	COVID-19 Case	-	46	135	217	Home	No	02:01, **24:02**	**07:02**
CA11	69	M	Heparinized blood	COVID-19 Case	-	66	128	233	Home	No	02:01, 03:01	**07:02**, 27:05
CA12	72	F	Heparinized blood	COVID-19 Case	11	38	-	-	Ward	Supplemental	02:01	**07:02**, 15:18
CA13	74	M	Heparinized blood	COVID-19 Case	-	90	178	270	Home	No	03:01, 26:01	**07:02**, 40:01
CA14	38	M	Heparinized blood	COVID-19 Case	6	41	-	-	Ward	No	**02:01**	15:01, 37:01
CA15	50	F	Heparinized blood	COVID-19 Case	8	-	-	-	Ward	Nasal prong	**02:01**, 68:01	15:01, 40:01
CA16	51	M	Heparinized blood	COVID-19 Case	11	-	-	-	Ward	No	**02:01**, 03:01	07:02, 39:10
CA17	52	F	Heparinized blood	COVID-19 Case	5	-	-	-	ICU	High flow nasal prong	**02:01**, 68:01	08:01, 44:02
CA18	54	M	Heparinized blood	COVID-19 Case	-	46	-	-	Ward	No	**02:01**, 31:01	38:01; 44:03
CA19	56	M	Heparinized blood	COVID-19 Case	-	145	-	-	Home	No	**02:01**, 26:01	44:02
CA20	58	M	Heparinized blood	COVID-19 Case	-	71	-	-	Home	No	**24:02**	35:01, 55:01
CA21	75	M	Heparinized blood	COVID-19 Case	-	121	-	-	Home	No	01:01, **24:02**	08:01, 14:02
SU1	20	M	Heparinized blood	Suspected case	-	~160^	-	-	Asymptomatic/ overseas	-	-	-
SU2	20	M	Heparinized blood	Suspected case	-	~160^	-	-	Asymptomatic/ overseas	-	-	-
SU3	20	M	Heparinized blood	Suspected case	-	~160^	-	-	Asymptomatic/ overseas	-	-	-
SU4	20	M	Heparinized blood	Suspected case	-	~160^	-	-	Asymptomatic/ overseas	-	-	-
PP1	21	M	Heparinized blood	Pre-pandemic Adult	-	-	-	-	-	-	-	-
PP2	23	M	Heparinized blood	Pre-pandemic Adult	-	-	-	-	-	-	-	-
PP3	24	M	Heparinized blood	Pre-pandemic Adult	-	-	-	-	-	-	-	-
PP4	26	M	Heparinized blood	Pre-pandemic Adult	-	-	-	-	-	-	-	-
PP5	27	M	Heparinized blood	Pre-pandemic Adult	-	-	-	-	-	-	-	-
PP6	28	M	Heparinized blood	Pre-pandemic Adult	-	-	-	-	-	-	-	-
PP7	31	M	Heparinized blood	Pre-pandemic Adult	-	-	-	-	-	-	-	-
PP8	31	M	Heparinized blood	Pre-pandemic Adult	-	-	-	-	-	-	-	-
PP9	3	F	Tonsil/ Heparinized blood	Pre-pandemic Child	-	-	-	-	-	-	03:01	**07:02**
PP10	5	M	Tonsil/ Heparinized blood	Pre-pandemic Child	-	-	-	-	-	-	03:01	**07:02**, 57:01
PP11	7	F	Tonsil/ Heparinized blood	Pre-pandemic Child	-	-	-	-	-	-	01:01, 03:01	**07:02**, 08:01
PP12	15	M	Tonsil/ Heparinized blood	Pre-pandemic Child	-	-	-	-	-	-	03:01	**07:02**, 14:01
PP13	30	M	Buffy pack	Pre-pandemic Adult	-	-	-	-	-	-	01:01, **24:02**	**07:02**, 57:01
PP14	35	F	Buffy pack	Pre-pandemic Adult	-	-	-	-	-	-	01:01, 03:01	**07:02**, 08:01
PP15	36	F	Buffy pack	Pre-pandemic Adult	-	-	-	-	-	-	02:01, 02:05	**07:02**, 41:01

PP16	45	N/A	Buffy pack	Pre-pandemic Adult	-	-	-	-	-	-	03:01, 11:01	**07:02**, 15:01
PP17	47	M	Heparinized blood	Pre-pandemic Adult	-	-	-	-	-	-	03:01, 26:01	**07:02**, 15:01
PP18	49	M	Buffy pack	Pre-pandemic Adult	-	-	-	-	-	-	01:01, 31:01	**07:02**, 08:01
PP19	55	M	Buffy pack	Pre-pandemic Adult	-	-	-	-	-	-	02:01; 03:01	**07:02**; 57:01
PP20	60	N/A	Buffy pack	Pre-pandemic Adult	-	-	-	-	-	-	24:02, 25:01	**07:02**, 18:01
PP21	63	N/A	Buffy pack	Pre-pandemic Adult	-	-	-	-	-	-	03:01, 26:01	**07:02**, 44:02
PP22	65	F	Buffy pack	Pre-pandemic Elderly	-	-	-	-	-	-	02:01,03:01	**07:02**, 44:03
PP23	69	N/A	Buffy pack	Pre-pandemic Elderly	-	-	-	-	-	-	02:01, 32:01	**07:02**, 44:03
PP24	69	N/A	Buffy pack	Pre-pandemic Elderly	-	-	-	-	-	-	11:01	**07:02**
PP25	72	N/A	Buffy pack	Pre-pandemic Elderly	-	-	-	-	-	-	02:01,11:01	**07:02**, 44:02
PP26	73	N/A	Buffy pack	Pre-pandemic Elderly	-	-	-	-	-	-	01:01, 03:01	**07:02**, 08:01
PP27	76	M	Buffy pack	Pre-pandemic Elderly	-	-	-	-	-	-	01:01	**07:02**, 08:01
PP28	76	F	Heparinized blood	Pre-pandemic Elderly	-	-	-	-	-	-	01:01, 31:01	**07:02**, 44:03
PP29	24	M	Heparinized blood	Pre-pandemic Adult	-	-	-	-	-	-	02:03, **24:02**	27:06, 40:01
PP30	59	M	Heparinized blood	Pre-pandemic Adult	-	-	-	-	-	-	**24:02**	07:02
PP31	32	M	Heparinized blood	Pre-pandemic Adult	-	-	-	-	-	-	01:01, **24:02**	07:06, 15:02
PP32	35	M	Spleen	Pre-pandemic Adult	-	-	-	-	-	-	1, 68	**7**, 18
PP33	41	F	Spleen	Pre-pandemic Adult	-	-	-	-	-	-	2, 25	**7**, 8
PP34	46	M	Spleen	Pre-pandemic Adult	-	-	-	-	-	-	02:01, 03:01	**07:02**, 57:01
PP35	49	M	Spleen	Pre-pandemic Adult	-	-	-	-	-	-	2, 3	**7**, 57
PP36	59	M	Spleen	Pre-pandemic Adult	-	-	-	-	-	-	2	**7**
PP37	63	F	Spleen	Pre-pandemic Adult	-	-	-	-	-	-	02:01, 24:02	**07:02**, 15:01
PP38	22	M	Lung	Pre-pandemic Adult	-	-	-	-	-	-	2, 32	**7**, 8
PP39	41	F	Lung	Pre-pandemic Adult	-	-	-	-	-	-	2, 25	**7**, 8
PP40	60	F	Lung	Pre-pandemic Adult	-	-	-	-	-	-	3	**7**, w6

*Days are calculated from first positive PCR result for CA1 after returning home from overseas for ~3 months.

[#]Days are approximate after they experienced mild symptoms while travelling overseas with CA1 and CA3.

^Days are approximate from the time they travelled overseas with suspected COVID-19, but PCR-negative on return.

HLA in bold were analysed for COVID-19-specific T cell responses or TCRs.

Table S2. B7/N105^{+}CD8^{+} TCRab repertoires. Related to Figure 5.

TRBV	TRBJ	CDR3β	TRAV	TRAJ	CDR3α	#80	CA5	CA2	CA4	BP124	BP155	BP161	BP160
20-1	2-1	CSARDTAGATYNEQFF	ND	ND	ND						1		
20-1	2-1	CSAWRGRGADNEQFF	ND	ND	ND					1			
28	2-3	CASTPMGLEVLDTQYF	ND	ND	ND							1	
28	2-5	CASSDRGMGETQYF	ND	ND	ND							1	
29-1	2-5	CSVVGTGGPETQYF	ND	ND	ND							1	
29-1	2-7	CSVVPLAGPYEQYF	ND	ND	ND							2	
7-2	1-1	CASRGGGTEAFF	ND	ND	ND			4					
28	2-1	CASSSLASSSYNEQFF	1-1	16	CAVRG#FSDGQKLLF				1				
6-5	2-1	CASSYYGVNEQFF	1-1	39	CAVT#NAGNMLTF						1		
18	1-3	CASSQGPYSGNTIYF	1-1	40	CAVRTP#TSGTYKYIF							1	
27	1-4	CASSLLAGGRAADKEKLFF	1-2	18	CAA#DRGSTLGRLYF						1		
2	2-4	CASSEEIAKNIQYF	1-2	31	CAVRVFNARLMF			1					
5-4	2-4	CASSLETGRNIQYF	1-2	35	WAIGFGNVLHC				2				
20-1	1-6	CSARDRTDSYNSPLHF	1-2	43	CADANNDMRF				1				
ND	ND	ND	1-2	6	CAVRDRGLTGGSYIPTF					1			
2	2-1	CASSELDGRL	10	18	CVVSSTLGRLYF							1	
27	2-4	CASSPLTGPPVAKNIQYF	10	20	CVPRA#KLSF		1						
27	2-4	CASNPLAGEFTAKNIQYF	10	31	CVVNGRDARLMF				9				
4-1	2-7	CASSPGTSYEQYF	10	42	CVVSAH#YGGSQGNLIF					1			
2	2-1	CASSEAELAGGQL#SYNEQF	12-1	12	CVVNVRVDSSYKLIF			1					
20-1	2-7	CSASGRDSVYEQYF	12-1	8	ND			1					
9	2-2	CASSVTANTGELFF	12-2	16	CAVTRFSDGQKLLF	1							
28	1-6	ND	12-3	13	CAMSLGPGGYQKVTF			1					
25-1	2-1	CASSGLTSAKNEQFF	13-1	11	CAASPLGGYSTLTF				1				
29-1	2-3	CSVDALLGAYTQYF	13-1	20	CAALPSADYKLSF			2					
20-1	2-7	CSAATRDRVYEQYF	13-1	21	NFNKFYF			1					
28	1-2	CASSGLTSDRAKYGYTF	13-1	3	CAASXXQTVXQXXX#				1				
6-5	1-1	CASSYSNPGQGAEAFF	13-1	4	LCXXPXXXXXQ*XX#F				1				
29-1	2-7	CSVVPLAGPYEQYF	13-1	44	CAALAGTASKLTF							8	
29-1	2-7	CSVVPLMGGYEQYF	13-1	44	CACLTGTASKLTF				2				
10-3	2-3	CAISDYPGPKTQDTQYF	13-1	9	ND	1							
12-3	2-2	CASSAGLAGANTGELFF	13-2	16	CAENQRFSDGQKLLF					1			
5-5	2-2	CASIPTRDTGELFF	13-2	17	CAENLL#AAGNKLTF				1				
ND	ND	ND	13-2	28	CAEIKRSGAGSYQLTF					1			
ND	ND	ND	13-2	49	CADPNTGNQFYF								26
14	2-7	CASSRVPQGTGSYEQYF	13-2	49	XAXXNTXXXFYF							1	
7-6	2-7	CASSRRWGSSYEQYF	13-2	49	CADPNTGNQFYF								1
9	2-3	CASSPTDNF	13-2	49	CADPNTGNQFYF								3
25-1	2-3	CASSPGDTQYF	13-2	50	CAEKTSYDKVIF							1	
11-2	2-7	CASSHLMAGGRYEQYF	14/DV4	13	XXXXXXSGXDHKXXF					1			
20-1	2-1	CSARRGLNEQFF	14/DV4	20	CAMREGYSNDYKLSF						1		
2	1-3	CAAVRPSTIYF	14/DV4	29	CAMRGSGNTXXXF				1				
20-1	2-1	CSARGGFRSGGGTDEQFF	14/DV4	31	CAMREGRSARLMF		3						
9	2-7	CASSLGTGPFSEQYF	14/DV4	37	CXMRGXXSNTGKLIF	1							
9	2-1	CASSSKPGGDYNEQFF	14/DV4	9	CAITGGFKTIF				2				
ND	ND	ND	16	12	CAEGGDSSYKLIF					1			
4-1	2-7	CASSQWSGPSYEQYF	16	37	CALP#SSNTGKLIF					1			
7-9	1-5	CASSLTGSRNQPQHF	16	39	CXIRNFWQATXS#F		1						
5-6	1-5	CASSRRATGNYQPQHF	16	8	XAXLI#VF							1	
24-1	2-3	CATSDLVSDTQYF	17	13	CDTAPERGGYQKVTF				1				
7-9	2-1	ND	17	21	CVGADNFNKFYF			2					
4-1	2-5	CASSQDGPRGQETQYF	17	22	CATDLIVSARQLTF		1						
27	1-1	CASWTGAAEAFF	17	24	CATDGVTDSWGKLQF				1				
29-1	2-2	CSVQGRGELFF	17	34	CATAGSYNTDKLIF					1			
28	2-1	CASNLRVDEQFF	17	47	XXXEWDGNKLVF			1					
4-1	1-1	CASSQSPGGTEAFF	17	48	CATDD#GNEKLTF	1							
6-6	2-7	CASRQLAGFYEQYF	17	57	CATDAGPEKLVF	1	21						
25-1	1-1	CASSGLTDANTEAFF	19	11	CALTRSGYSTLTF		1						
4-2	2-1	CASSQTYPGAYNEQFF	19	11	CALSEAGSGYSTLTF				1				
19	2-1	CASSISGGYNEQFF	19	17	CALITIKAAGNKLTF		1						
29-1	2-7	CSVETPGVYEQYF	19	20	XAVXFRAXKDYKLSF						1		
2	1-4	CARRQGNEKLFF	19	26	CALSVNYGQNFVF						1		
14	2-2	CASSQVLGPGELFF	19	30	YFCXXSERSRXDKIIF				1				
9	2-3	CASSPTDNF	19	36	CALSVLTGANNLFF								1
9	2-1	CASSARDF	19	54	CALSEIQGAQKLVF						1		
9	2-7	CASGSGGEHF	19	56	CALSRVGANSKLTF						1		
20-1	1-6	CSATDRAASYNSPLHF	20	13	CAVQGQNSGGYQKVTF			2					
5-5	2-5	CASSFTIAA#QETQYF	21	13	CAVLNSGGYQKVTF					1			
20-1	2-1	CSARAGIREGFYNEQFF	21	21	CGLRDNFNKFYF			1					
27	2-4	CASSTIAGETKNIQYF	21	30	CAVPIMNRDDKIIF		1						
20-1	1-5	CSATDRANVNQPQHF	23/DV6	40	CAASITPGTYKYIF			1					
24-1	1-2	CATSDPTDRVDGYTF	24	40	CAFISTSGTYKYIF				1				
28	2-2	CASSFLTSANTGELFF	26-1	4	CIVRVGPGGYNKLIF			1					
2	1-1	CASRLANTEAFF	26-1	53	CIVRLGGLGGGSNYKLTF		1						
9	1-6	CASSVEGTVNSPLHF	26-2	12	CILRTPLDSSYKLIF	1							
6-1	2-4	CASSDIFLAKNIQYF	3	29	CAVRVLNTPLVF					1			
2	1-5	CASSEAISTRAQHF	3	3	CXLREQWX#KIIF				1				
29-1	1-1	ND	3	30	ND			1					
9	2-1	CASSVSGGAYNEQFF	3	31	CAVRDYNNARLMF	26							
5-6	1-2	CASSLGRAVIWGYTF	3	37	CAPPRGSSNTGKLIF	1							
24-1	2-1	CATSDLTGANEQFF	36/DV7	13	CAGDSGGYQKVTF			1					
3-1	2-3	CASSQDLASSTDTQYF	38-1	4	CAFLFSGGYNKLIF			1					
ND	ND	ND	38-1	44	CAFMKHRTGTASKLTF						1		
4-1	1-6	CASSQDQGAGSPLHF	4	10	VLXGGXXXXXF						1		
5-4	2-1	CASSPPTGNEQFF	4	10	CLVGDQGAGGGNKLTF			1					
6-1	2-7	CASSDRTGRRNEQYF	4	10	CLVAAPGNKLTF					1			
7-2	1-5	CASSLATGSGNQPQHF	4	10	CLVGDQILTGGGNKLTF				1				
7-3	2-5	CASSLGTGAQETQYF	4	10	CLVATILTGGGNKLTF						1		
30	2-2	CAWDYLTLNTGELFF	4	13	CXVGDSHCGGYQKVTF				1				
2	2-1	SPAVHRVANNEQLF	4	16	CLVGAYGQRLLF					1			
4-2	2-7	CASSQSGTGPYEQYF	4	18	CLVGDRGSTLGRLYF					1			

7-2	2-7	CASSPSSREQYF	4	21	CLVVGFNKFYF					1			
2	2-7	CASSGLNDRFYEQYF	4	22	CLVGVPFSGSARQLTF					1			
12-3	1-1	CASRQRGGRVNXEAFF	4	23	CLVGDPFWNQGGKLIF						1		
4-1	2-1	CASSQVRGPQFF	4	23	CLVGDQGGKLIF						1		
ND	ND	ND	4	27	CLVGDMNTNAGKSTF								2
20-1	1-5	ND	4	29	CXXQGGNTHLIW						1		
ND	ND	ND	4	3	CXXGDSXXSKIIF					1			
11-2	1-4	CASSLFRGGEKLFF	4	30	CLLYRDDKIIF					1			
2	2-7	CASRTPGTSGGSYEQYF	4	30	CLVGDPSPRRDDKIIF						1		
ND	ND	ND	4	32	CLVGDKTPGATNKXIF					1			
4-1	2-2	CASSHNGELFF	4	32	CLVDGGATNKLIF								1
2	2-2	CASSLNRELFF	4	39	CLVVGRYAGNMLTF								1
5-6	1-1	CASSLLLRDGGRGAFF	4	39	CLVGGWDAGNMLTF								1
6-5	1-3	CASRGQRNTIYF	4	39	CLVGDPLNNAGNMLTF					1			
14	2-7	CASSPMGHEQYF	4	4	CLVGDQGGGYNKLIF		1						
29-1	2-3	CSVERGDTQYF	4	4	CLVGVFXGGXNKLIF								1
29-1	1-1	CSVPGTGNEAFF	4	40	ND						1		
10-3	2-7	CAIRIKGH*AXATSS#F	4	41	CLVSSGYALNF						1		
20-1	2-2	CSAGGLAAPGELFF	4	42	XXVGXXKXGGSQGNLIF						1		
5-4	2-1	CASSRLAGGRNEQFF	4	45	CLMYSGGGADGLTF					1			
11-3	1-2	CASSSFPGREMTF	4	5	CLVGDPMDTGRRALTF					1			
3-1	2-6	ND	4	6	CLVGDVGGSYIPTF					1			
7-9	ND	ND	41	50	CAVRSR#TSYDKVIF						1		
28	2-3	CASSLGVAGTDTQYF	41	58	CAREIGSRLTF				1				
29-1	2-7	CSVVPLAGPYEQYF	6	3	CAG#GYSSASKIIF						1		
24-1	2-2	CATSPLAGEYSGELFF	6	35	CALVVGFGNVLHC			1					
25-1	2-7	CASSPLLGGGFAEQYF	6	35	CAP#FGNVLHC						1		
20-1	1-6	CSAKPRENWNSPLHF	6	38	CALDPQXGNNRKLIW						1		
29-1	2-7	CSVVPLAGPYEQYF	6	38	XGFEXRAGNNTKLFW								1
15	2-5	CATSRRTVLRETQYF	6	43	CALGVNNDMRF						1		
28	2-7	CASMGLAGGGEQYF	6	6	CALDPR#SGGSYIPTF				1				
6-5	2-1	CASSYGMGGRASYNEQFF	6	8	CALE#NTGFQKLVF			1					
29-1	2-5	CSVSGQKEETQYF	8-1	12	CAPPDSSYKLIF								1
9	1-6	CASSSFPGPQPNSPLHF	8-1	16	CAVITSDGQKXXF			1					
6-2	2-1	CASAALAAYNEQFF	8-2	13	CAGGYQKVTF					1			
6-1	2-2	CASVGLAVVGELFF	8-2	16	CAVFADGQKLLF				1				
5-6	2-6	CASTPKPFSGANVLTF	8-2	28	CVVSR*HR#GAGSYQLTF						1		
15	2-1	CATSGTGTSGRNEQFF	8-2	3	CAVPSYSSASKIIF				1				
28	1-1	CASTPLGTSSFLNTEAFF	8-2	4	CVVSEAGGYNKLIF				1				
6-5	1-1	ND	8-2	41	CAVSSYSNSGYALNF						1		
27	2-4	CASSPIAGGPISKNIQYF	8-2	44	CAVSATGTASKLTF			1					
6-2	1-6	ND	8-2	48	CAVPNFGNEKLTF			1					
14	2-2	CASSRLAGGNTGELFF	8-2	9	CVVANGFKTIF						1		
3-1	1-2	CASSQPAGYGGYTF	8-3	16	CAVVGFSDGQKLLF						1		
27	2-4	CASRALTGHPDAKNIQYF	8-3	34	CAVGARNTDKLIF				1				
29-1	2-5	CSVVGTGGPETQYF	8-4	15	CAVMRGTALIF								1
6-6	2-7	CASSYLPGPPAGEQYF	8-4	27	CAVTPP#NAGKSTF			1					
18	2-5	CASSPADRTSLEGETQYF	8-4	29	CAVSA#SGNTPLVF								1
7-2	2-7	CASSSGGYEQYF	8-4	3	CAVPTYSSASKIIF								1
3-1	2-1	CASQPLAGGPNEQFF	8-4	39	CAVITSNNAGNMLTF						1		
ND	ND	ND	8-4	43	CTVSAKPNDMRF								1
6-1	1-1	CASSPDRALPEAFF	8-4	48	CAVPNFGNEKLTF			1					
28	2-5	CASSSLTGQSQETQYF	8-4	5	CVGRDTGRRALTF			5					
7-9	2-7	CASSPGTSGRPYEQYF	8-6	31	CAVSETGPARLMF				1				
14	1-3	CASTGPGRRSGNTIYF	8-6	36	CAVTG#QTGANNLFF						1		
9	1-2	ASKLWASGSGYGYTF	8-6	5	CAVRL*#DTGRRALTF	1							
27	1-2	CASRGGGQGGSYGYTF	8-6	52	CAGGGYGKLTF				1				
27	2-3	CASSTRTGGFSDTQYF	8-6	6	CAVSVLY#SGGSYIPTF				1				
14	2-1	CASSGLAGGYNEQFF	8-6	9	CAARLSFKTIF						1		
19	1-2	CASSTLGTADKLNYGYTF	9-2	23	CALSVGNQGGKLIF			4					
27	2-1	CASSSLTSGAHNEQFF	9-2	39	CALTRNNAGNMLTF	1							
11-3	2-1	ND	9-2	40	CALSSTSGTYKYIF			1					
14	1-3	CAXTGPGRRSKNTHIF	9-2	40	CALSATSGTYKYIF						1		
27	2-5	CASSPLSGTSATKETQYF	9-2	40	CALSATSGTYKYIF								1
10-3	2-3	CAISDYPGPKTQDTQYF	9-2	9	CAXSDRGGGFKTIF	1							
					Total	**36**	**32**	**40**	**39**	**24**	**31**	**31**	**31**

Ac = acute; F_{up} = follow-up convalescent sample; ND, not determined; X = any amino acid; # indicates an out-of-frame shift; * = stop codon.

Table S3. A2/S269^{+}CD8^{+} TCRαβ repertoires. Related to Figure 6.

TRBV	TRBJ	CDR3β	TRAV	TRAJ	CDR3α	#020 Ac	#89 Ac	#89 Fup	CA6	CA7	CA2
19	2-2	CATQNMNTGELFF	ND	ND	ND						1
2	2-2	CASSEIDTGELFF	ND	ND	ND		1				
7-9	2-7	CASSPDIEQYF	ND	ND	ND					1	
4-2	2-3	CASSQTESTDTQYF	1-1	37	CAHWGSSNTGKLIF						1
3-1	2-2	CASQLQNTGELFF	1-2	38	XAVRDNAGXXXKXIW						1
20-1	2-2	CSARDPRAQNTGELFF	1-2	4	CAGPPNKLIF						1
20-1	1-2	CSAQTDRNLGGYTF	10	39	CVVSAR#AGNMLTF		2				
3-1	2-2	CAVQGMNTGELFF	10	55	ND		1				
28	2-2	CASSPTGGGNTGELFF	12-1	11	CVVNEPLSGYSTLTF		1				
29-1	2-2	CSARGLAEANTGELFF	12-1	15	CVVNIPQAGTALIF		1	2			
13	2-2	CASSFPGGGNTGELFF	12-1	24	CVVNAADSWGKLQF						1
20-1	2-2	CSARGGQGLNTGELFF	12-1	29	CVVNLPEGNTPLVF						1
7-9	2-7	CASSLDIEQYF	12-1	30	CVVNKYDKIIF						1
7-9	2-7	CASSLDIEQYF	12-1	31	XVVNXXDRLMX			1			
12-3	2-2	CALGEQNTGELFF	12-1	34	CVVNKDDKLIF		1				
2	2-2	CASPNQNTGELFF	12-1	34	CVVNGNTDKLIF		1				
7-9	2-2	CARGLANTGELFF	12-1	34	CVVNGADKLIF		1				
12-3	2-2	CASINLNTGELFF	12-1	39	CVVNSHAGNMLTF						1
29-1	2-2	CSVEADRNTGELFF	12-1	41	CVVNKDSGYALNF						1
11-2	2-2	ND	12-1	43	CVVNNNNDMRF			1			
12-3	2-2	CALGDLNTGELFF	12-1	43	CVVNRNNDMRF						1
12-3	2-2	CASGKQNTGELFF	12-1	43	CVVNEKDDMRF						1
12-3	2-2	CAAGQGNTGELFF	12-1	43	CVVNRADDMRF						1
12-3	2-2	CASINLNTGELFF	12-1	43	CVVNNNNDMRF						1
12-3	2-2	CARGDANTGELFF	12-1	43	CVVNNNNDMRF						2
19	2-2	CAGQVTNTGELFF	12-1	43	CVVNRNNDMRF				1		
2	2-2	CASSDLNTGELFF	12-1	43	CVVNGGNDMRF		1				
2	2-2	CASSDLNTGELFF	12-1	43	CVVNGNNNDMRF		1				
2	2-2	CASSEIDTGELFF	12-1	43	CVVNRNNDMRF		1				
2	2-2	CASGQLNTGELFF	12-1	43	CVVNRGNDMRF						1
2	2-2	CASNDLNTGELFF	12-1	43	CVVNKGNDMRF						1
2	2-2	CASQDTNTGELFF	12-1	43	CVVNKGNDMRF				1		
2	2-2	CAVEGNLNTGELFF	12-1	43	CVVNNNNDMRF						1
20-1	2-2	CSARDRQGQNTGELFF	12-1	43	CVVXSFDDMRF						1
24-1	2-2	CATQRANTGELFF	12-1	43	GVVNMGDDMRF		1				
3-1	2-2	CAVQGMNTGELFF	12-1	43	CVVNNNXDMRF		1				
5-1	2-2	CASGEENT#GELFF	12-1	43	CVVNKNNDMRF			1			
5-4	2-2	CASSPDRNTGELFF	12-1	43	CVVNVMDDMRF		1				
5-8	2-2	CAIIDRNTGELFF	12-1	43	CVVNREDDMRF						1
6-5	2-2	CATTSLNTGELFF	12-1	43	CVVNRDNDMRF			1			
7-8	2-2	CASGQLNTGELFF	12-1	43	CVVNNNNDMRF			1			
7-8	2-2	CASYFQDTGELFF	12-1	43	XVVNGXXDMXF		1				
7-8	2-7	CASSAGVSGEQYF	12-1	43	CVVNVVDDMRF			2			
7-9	2-3	CASSLDIEQYF	12-1	43	CVVNSFDDMRF					1	
29-1	2-2	CSARTSGGQNTGELFF	12-1	47	XVXNREDKLVF		1				
7-9	1-1	CASSPDIVAFF	12-2	30	CAVNRDDKIIF						1
7-9	1-1	CASSLDIEAFF	12-2	30	CAVNGDDKIIF		1	1			
7-9	2-1	CASSFDIAEFF	12-2	30	CAVNQDDKIIF		1				
7-9	2-7	CASSPDIEQYF	12-2	30	CAVNRDDKIIF	1				1	
9	2-5	XPXXGXXXX	13-1	21	CAVQNFNKFYF					1	
20-1	2-2	CSARDPLAINTGELFF	13-1	28	CAAS#YSGAGSYQLTF		1				
20-1	2-2	CSARDPLAINTGELFF	13-1	29	ND		1				
7-9	2-1	CASSPDIDQFF	13-1	3	CAATPE#SSASKIIF				1		
7-3	1-5	CASSPDDGQPQHF	13-1	39	XPXXRXXXXQX##TF						1
7-8	2-2	CGELAQNTGELFF	13-1	47	CAAFGXXKQ##VF				1		
2	1-1	CASPKRTGLSNTEAFF	13-1	48	XXXXXXXXX##F						1
9	2-2	CASSEENTGELFF	13-2	3	CAEPSSASKIIF		1				
2	2-2	CASQNRDTGELFF	13-2	35	CAES#IGFGNVLHC						2
20-1	2-2	CSARGKREHNTGELFF	13-2	42	CAENSHPRGGGSQGNLIF		1				
7-9	2-2	CAPGVPNTGELFF	13-2	49	CADT##NTGNQFYF		1				
25-1	2-2	CALQDXNTGEXFF	14/DV4	20	CAMRE#SNDYKLSF		1				
24-1	2-1	CATSGPLPR*#SYNEQFF	14/DV4	21			1				
15	2-2	CATTEGVAGELFF	14/DV4	27	ND						1
27	2-7	CASSDRGRSYEQYF	14/DV4	28	CAMREAPFAYSGAGSYQLTF				1		
ND	ND	ND	14/DV4	41	CAMREGSGYALNF						1
15	2-2	CATTEGVAGELFF	14/DV4	42	CATR##GSQGNLIF						3
9	2-7	CASSVEPGWDEQYF	14/DV4	48	CAMRGAGNEKLTF					1	
19	2-7	CASSIGDEQYF	14/DV4	5	LLLCRDC#DTGRRALTF				1		
19	2-3	CASSIDLADTQYF	16	15	CAXPXACXXC##IF						1
6-1	2-2	CASQRMNTGELFF	16	37	CALQ#GSSNTGKLIF						1
24-1	2-1	CATSGPLPR*#SYNEQFF	16	42	CALSD#YGGSQGNLIF		1				
7-8	1-2	CASSDSYGYTF	16	42	CALSD#YGGSQGNLIF			1			
2	2-2	CASTRDLNTGELFF	16	43	CALGGRVDNDMRF			1			
ND	ND	ND	17	16	CGGGGQKLLF		1				
20-1	2-2	CSARDPWGINTGELFF	17	29	VXXVSSGNTHLXF			1			
7-8	2-2	CASSFQDTGELFF	17	52	CVXXIXXWXXXXXK##TF						1
6-6	2-2	CASENRNTGELFF	17	54	CAPEIQGAQKLVF			1			
19	2-2	CASQTLNTGELFF	19	47	CALTPLRPKLVF			1			
13	2-2	CASSPLQGGNTGELFF	21	28	ND		2				
7-8	2-2	CASSLQNTGELFF	21	30	ATYLCAAGDDKIIF		1				
5-1	2-2	CASGDENTGELFF	23/DV6	34				1			
7-9	2-2	CAGGEPNTGELFF	23/DV6	34	CAASRADKLIF		1				
2	2-2	CAINEQNTGELFF	23/DV6	35	CAASXXXXAXGMX#HC						1
7-9	1-1	CASSPDIEAFF	23/DV6	4	XAASRNLXWXXQ*##IF						1
15	2-2	CATQEGNTGELFF	23/DV6	44	CAV*TGTASKXTF						1
10-2	2-2	CASLVQENTGELFF	23/DV6	45	ND		1				
20-1	2-2	CSAPSYGELFF	23/DV6	49	CAADYTGNQFYF						1
4-2	2-3	CASSQVESADTQYF	23/DV6	49	CAAXYXXXQXYX				1		
27	1-5	CASSYSSYGSNQPQHF	24	28	XXXXWGXGSXQLTX						1
4-2	2-2	CATQDANTGELFF	25	42	CAGLGDGGSQGNLIF		1				

11-2	2-3	CASSLGWDGNTDTQYF	25	43	GLNDMRF						1
20-1	2-2	CSARDALAQNTGELFF	26-1	43	XSXLHPRGEQXQXHX#F		1				
19	2-2	CATQITNTGELFF	27	30	CAGP#MNRDDKIIF						1
7-9	1-2	CASSDSLGYTF	27	42	XXXXXXXXQXXX#		1				
27	2-3	CAKTGIA#QYF	29/DV5	17	CAASALWA#AGNKLTF		1				
4-1	2-3	CASQLVNTGELFF	29/DV5	21	CAAS*RNFNKFYF						1
20-1	2-2	CSAGDLNTGELFF	29/DV5	26	CAATNGSNYGQNFVF		2	1			
7-9	2-2	CASSNDPNTGELFF	29/DV5	31	#RLMF						1
29-1	2-2	CSARGLAEANTGELFF	3	17	CAVS#KAAGNKLTF		6				
29-1	2-2	CSVTWDRNTGELFF	3	34		1					
6-5	2-5	CASSYPTGEGQETQYF	3	34	CAVRDKNTDKLIF		2	2			
15	2-2	CATGELNTGELFF	35	42	CAGPPPR#GSQGNLIF		2				
20-1	2-2	CSAQGDLNTGELFF	35	42	CAGQC#GSQGNLIF		1				
7-9	2-2	CASGEGNTGELFF	35	49	CAGQGGET#FYF						1
28	2-2	CASSYKNTGELFF	35	52	CAGPT#GGTSYGKLTF						1
12-3	2-3	CASSFARAQADTQYF	38-2/DV8	31	CALMSARLMF				1		
28	2-7	CASSLETAGEQYF	39	49	CAVDMDTGNQFYF			1			
29-1	2-7	CSVDRGSPSYEQYF	41	45	CAVREGADGLTF						1
18	2-7	CASRDGRESYEQYF	41	48	CAVIPDFGNEKLTF				1		
2	1-1	CASSPRNSLEAFF	41	57	CAVQP#QGGSEKLVF						1
2	2-2	CASQDRNTGELFF	5	14				1			
2	2-2	CASSGGQGANTGELFF	5	23	CAEKAY##NQGGKLIF		1				
7-9	1-1	CASSPDIEAFF	5	30	PPTXVP#NRDDKIIF						1
7-9	2-1	CASSLAGPNEQFF	5	36	XAEEDQXGANNXXF				1		
7-3	2-1	CASSTPLENEQFF	5	37	CAEEGNTGKLIF						1
20-1	1-4	CSARDPSGVKLFF	5	48	CAEILDFGNEKLTF		2	13			
10-3	2-5	CAISDGDWETQYF	6	23	ND						1
2	2-2	CASSDLDTGELFF	6	43	CALDVAL#NDMRF						1
7-9	2-2	CASNNANTGELFF	6	49	CALVGNQFYF				2		
19	2-2	CASQILNTGELFF	8-1	50	XXVNVSPKEXXXRQXXX#						1
20-1	1-2	CSARDFLGGYTF	8-2	8	XXXSDXXEXRXSXXXI#						1
20-1	1-4	CSARDPSGVKLFF	8-2	8	XXXXIGXXXGXXKXFF			1			
2	2-2	CASSELNGGNTGELFF	8-3	22	S#SGSARQLTF						1
2	2-2	CASSELDSGELFF	8-4	27	CAVLPQ#AGKSTF		1				
5-4	2-2	CASSPDRNTGELFF	8-4	34	CAVT*SYNTDKLIF		1				
5-1	2-2	CATSDSNTGELFF	8-4	52	CAVSR#AGGTSYGKLTF		1				
12-3	1-4	CASTLAGTGEEKLFF	8-6	11	CAYSGYSTLTF						1
7-8	2-2	CASSLGISGELFF	8-6	13	SA*#QKVTF			1			
20-1	2-7	CSAEGDRNSLRTYF	8-6	41	CAHVA#NSNSGYALNF						2
20-1	2-2	CSARWGLLVNTGELFF	8-6	6	S*GAGGSYIPTF					1	
28	2-2	CASSPTGGGNTGELFF	9-2	3	CAVRTY#SSASKIIF		3				
7-8	2-2	CAKQGLDTGELFF	9-2	37	CGGREL*QHRQ##IF		1				
5-1	2-2	CASSGLNTGELFF	9-2	43	CAXSDKXX#DMRF						1
2	2-2	CASSDLNTGELFF	9-2	45	CALSAPYSGGGADGLTF	1					
20-1	2-2	CSARDSLAQNTGELFF	9-2	5	CXXSSRAGEHL#F			1			
					Total	**3**	**60**	**37**	**12**	**6**	**57**

Ac = acute; F_{up} = follow-up convalescent sample; ND, not determined; X = any amino acid; # indicates an out-of-frame shift; * = stop codon.

Table S4. TCR diversity scores of pre-pandemic and COVID-19 TCRαβ repertoires. Related to Figure 7.

Epitope	Group	#Donors	#TCRαβ pairs	#TCRαβ clones	TCRdiv-α	TCRdiv-β	TCRdiv-αβ
A2/S_{269}*	COVID-19	4	43	35	34.8	101.0	147.9
A2/S_{269}	COVID-19	5	75	57	29.8	76.9	100.1
B7/N_{105}	Pre-pandemic	4	43	37	935.7	322.9	730.4
B7/N_{105}*	COVID-19	4	42	25	282.3	291	299.9
B7/N_{105}	COVID-19	4	82	42	809.8	831.9	860.6
A2/EBV*	Dash et al., 2017	4	46	17	5	9.2	6.6
A2/EBV	Dash et al., 2017	6	470	76	9.5	15.3	14.9
A2/M1*	Dash et al., 2017	4	43	19	15.4	8	16.9
A2/M1	Dash et al., 2017	15	453	275	21.3	5.8	21.4
A2/CMV*	Dash et al., 2017	4	48	9	36	35.4	36
A2/CMV	Dash et al., 2017	10	307	61	61.3	134	421.5

*TCRs were randomly subsampled from the full dataset for ease of comparisons to the smaller B7/N_{105} pre-pandemic and A2/S_{269} COVID-19 TCR datasets.